

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number  
**WO 01/85764 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/00

(21) International Application Number: PCT/EP01/05244

(22) International Filing Date: 9 May 2001 (09.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/203,582 11 May 2000 (11.05.2000) US  
60/269,857 21 February 2001 (21.02.2001) US

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RAMAKRISHNAN, Shyam [IN/US]; 76 Euston Road, Apt. #10, Brighton, MA 02135 (US).

(74) Common Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGULATION OF HUMAN P2Y-LIKE G PROTEIN-COUPLED RECEPTOR

(57) Abstract: Reagents which regulate human P2Y-like G protein-coupled receptor can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, diabetes, angina pectoris, myocardial infarction, ulcers, asthma, COPD, inflammation, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.



WO 01/85764 A2

## REGULATION OF HUMAN P2Y-LIKE G PROTEIN-COUPLED RECEPTOR

### TECHNICAL FIELD OF THE INVENTION

5

The invention relates to the area of G protein-coupled receptors. More particularly, it relates to the area of P2Y-like G protein-coupled receptors and their regulation.

### BACKGROUND OF THE INVENTION

10

#### *G Protein-Coupled Receptors*

Many medically significant biological processes are mediated by signal transduction pathways that involve G proteins (Lefkowitz, *Nature* 351, 353-354, 1991). The family of G protein-coupled receptors (GPCR) includes receptors for hormones, neurotransmitters, growth factors, and viruses. Specific examples of GPCRs include receptors for such diverse agents as dopamine, calcitonin, adrenergic hormones, endothelin, cAMP, adenosine, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G proteins themselves, effector proteins such as phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.

GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent hydrophilic loops. GPCRs (also known as 7TM receptors) have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are believed to stabilize functional protein structure. The seven transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 has been implicated in signal transduction.

Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some GPCRs. Most GPCRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus.

5 For several GPCRs, such as the  $\beta$ -adrenergic receptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains. The hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 has been implicated in several GPCRs as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters (*see Johnson et al., Endoc. Rev. 10, 317-331, 1989*). Different G-protein alpha-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs. For example, in one form of signal transduction, the effect of hormone binding is the activation inside the cell of the enzyme, adenylyl cyclase. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G protein connects the hormone receptor to adenylyl cyclase. G protein exchanges GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylyl cyclase. Hydrolysis of GTP to GDP, catalyzed by the G protein itself, returns the G protein to its basal, inactive form. Thus, the G protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

- 3 -

Over the past 15 years, nearly 350 therapeutic agents targeting GPCRs have been successfully introduced onto the market. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly, there is an on-going need for identification and characterization of further GPCRs which can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, cancers, anorexia, bulimia, asthma, chronic obstructive pulmonary disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, allergies, multiple sclerosis, benign prostatic hypertrophy.

GPCRs are of critical importance to both central and peripheral nervous system and novel GPCRs are therefore promising new targets for the treatment of nervous system disease, for example in primary and secondary disorders after brain injury, disorders of mood, anxiety disorders, disorders of thought and volition, disorders of sleep and wakefulness, diseases of the motor unit like neurogenic and myopathic disorders, neurodegenerative disorders like Alzheimer's and Parkinson's disease, disorders leading to peripheral and chronic pain.

Because of the wide-spread distribution of GPCRs with diverse biological effects, there is a need in the art to identify additional members of the GPCR family whose activity can be regulated to provide therapeutic effects.

#### P2Y-like receptors

Nucleotides are ubiquitous intercellular messengers whose actions are mediated by specific receptors e.g. P2Y receptors. Since the first clonings in 1993, it is known that nucleotide receptors belong to two families: the ionotropic P2X receptors and the metabotropic P2Y receptors. Five human P2Y receptor subtypes have been cloned so far and a sixth one must still be isolated [Williams and Jarvis, Biochemical



- 4 -

Pharmacology 59 (2000) 1173-1185]. P2Y receptors as purine and pyrimidine nucleotide receptors act via G protein coupling to activate PLC and adenylate cyclase [Ralevic and Burnstock, Pharmacological Reviews 50 (1998) 413-492]. ATP, acting via P2Y receptors as a fast excitatory neurotransmitter in nervous tissue, plays a critical role in tissue development, nociception, apoptosis, platelet aggregation, astroglial cell function, and metastasis formation. P2Y receptors have been reported to inhibit prejunctionally neurotransmission at the terminals of nerves. P2Y receptors are widely distributed on neurons, astroglia, microglia, and oligodendroglia. Compounds that produce their effects via purinoceptor systems comprise three distinct classes: (i) conventional agonist, partial agonist, or antagonist ligands; (ii) allosteric modulators of receptor function; and (iii) modulators of the enzyme systems regulating the extracellular availability of ATP, adenosine, UTP, and their respective nucleotides. Newer therapeutic targets under exploration for P2Y receptor ligands include inflammation, congestive heart failure, myocardial ischemia and (allgemeiner CNS Satz). Because of broad importance of P2Y receptors in the modulation of the function of the nervous system, there is a need in the art to identify related human receptors which can be regulated to provide therapeutic effects.

#### SUMMARY OF THE INVENTION

It is an object of the invention to provide reagents and methods of regulating a human P2Y-like G protein-coupled receptor. This and other objects of the invention are provided by one or more of the embodiments described below.

One embodiment of the invention is a P2Y-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

- 5 -

Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a P2Y-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

Binding between the test compound and the P2Y-like GPCR polypeptide is detected. A test compound which binds to the P2Y-like GPCR polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation.

Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a P2Y-like GPCR polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 4;

the nucleotide sequence shown in SEQ ID NO. 4;

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 5; and

the nucleotide sequence shown in SEQ ID NO. 5.

- 6 -

Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the amount of the P2Y-like GPCR through interacting with the P2Y-like GPCR mRNA.

5

Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a P2Y-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:

10

amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2; and

the amino acid sequence shown in SEQ ID NO. 2.

15

A P2Y-like GPCR activity of the polypeptide is detected. A test compound which increases P2Y-like GPCR activity of the polypeptide relative to P2Y-like GPCR activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation. A test compound which decreases P2Y-like GPCR activity of the polypeptide relative to P2Y-like GPCR activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.

20

Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a P2Y-like GPCR product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:

25

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 4;

30

- 7 -

the nucleotide sequence shown in SEQ ID NO. 4;

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 5; and

5

the nucleotide sequence shown in SEQ ID NO. 5.

Binding of the test compound to the P2Y-like GPCR product is detected. A test compound which binds to the P2Y-like GPCR product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

10

Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a polynucleotide encoding a P2Y-like GPCR polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

15

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 4;

20

the nucleotide sequence shown in SEQ ID NO. 4;

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO. 5; and

25

the nucleotide sequence shown in SEQ ID NO. 5.

P2Y-like GPCR activity in the cell is thereby decreased.

The invention thus provides a P2Y-like G protein-coupled receptor which can be used to identify test compounds which may act as activators or inhibitors (e.g.

30

agonist, antagonist, partial agonist, inverse agonist, co-activator) at the receptor site and which can be regulated to provide therapeutic effects.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5

Fig. 1 shows a genomic clone comprising the DNA-sequence encoding a P2Y-like GPCR polypeptide.

Fig. 2 shows the amino acid sequence of a P2Y-like GPCR polypeptide.

Fig. 3 shows the amino acid sequence of the chicken P2Y3 protein assigned  
10 GenBank Accession No. X98283.

Fig. 4 shows the DNA-sequence encoding a P2Y-like GPCR polypeptide.

Fig. 5 shows the DNA-sequence encoding a P2Y-like GPCR polypeptide.

Fig. 6 shows the alignment of P2Y-like GPCR polypeptide of Fig. 2 and the protein  
identified by Accession No. X98283 of Fig. 3.

15 Fig. 7 shows the relative expression of P2Y-like GPCR in various human tissues.

Fig. 8 shows the relative expression of P2Y-like GPCR in CNS specific panel.

Fig. 9 shows the relative expression of P2Y-like GPCR in various human respiratory  
tissues and cells (HBEC=cultured human bronchial epithelial cells;  
H441=Clara-like cells; SMC=cultured airway smooth muscle cells; SAE=  
20 cultured small airway epithelial cells; Alv. Type II=primary cultured alveolar  
type II cells; PMN=polymorphonuclear leukocytes; Mono=monocytes; Cult.  
Mono=cultured monocytes (macrophage-like)).

#### DETAILED DESCRIPTION OF THE INVENTION

25

The invention relates to an isolated polynucleotide encoding a P2Y-like GPCR polypeptide and being selected from the group consisting of:

- a) a polynucleotide encoding a P2Y-like GPCR polypeptide comprising an  
30 amino acid sequence selected from the group consisting of:

- 9 -

amino acid sequences which are at least about 50% identical to  
the amino acid sequence shown in SEQ ID NO. 2; and  
the amino acid sequence shown in SEQ ID NO. 2.

- 5      b)      a polynucleotide comprising the sequence of SEQ ID NOS. 4 or 5;
- c)      a polynucleotide which hybridizes under stringent conditions to a  
                 polynucleotide specified in (a) and (b);
- 10     d)      a polynucleotide the sequence of which deviates from the polynucleotide  
                 sequences specified in (a) to (c) due to the degeneration of the genetic code;  
                 and
- e)      a polynucleotide which represents a fragment, derivative or allelic variation of  
15             a polynucleotide sequence specified in (a) to (d).

Furthermore, it has been discovered by the present applicant that a P2Y-like GPCR,  
particularly a human P2Y-like GPCR, can be used in therapeutic methods to treat  
disorders such as bacterial, fungal, protozoan, and viral infections, particularly those  
20     caused by HIV viruses, cancers, anorexia, bulimia, asthma, chronic obstructive  
         pulmonary disease, cardiovascular diseases such as acute heart failure, hypotension,  
         hypertension, angina pectoris, and myocardial infarction, urinary retention,  
         osteoporosis, diabetes, inflammation, ulcers, allergies, multiple sclerosis, benign  
         prostatic hypertrophy.

25

The human P2Y-like G protein-coupled receptor is of critical importance to both  
central and peripheral nervous system and is therefore a promising new target for the  
treatment of nervous system disease, for example in primary and secondary disorders  
after brain injury, disorders of mood, anxiety disorders, disorders of thought and  
30     volition, disorders of sleep and wakefulness, diseases of the motor unit like

neurogenic and myopathic disorders, neurodegenerative disorders like Alzheimer's and Parkinson's disease, disorders leading to peripheral and chronic pain.

Human P2Y-like GPCR also can be used to screen for human P2Y-like GPCR  
5 activators and inhibitors.

An amino acid sequence of a human P2Y-like GPCR is shown in SEQ ID NO. 2. Transmembrane helices are present from amino acids 27-49, 62-84, 103-125, 138-160, and 185-207 of SEQ ID NO. 2. Using the BLASTP alignment algorithm, the  
10 amino acid sequence shown in SEQ ID NO. 2 is 45% identical over 185 amino acids to the chick P2Y3 protein assigned GenBank Accession No. X98283 (SEQ ID NO. 3) and annotated as a human G protein-coupled receptor. Human P2Y-like GPCR is therefore expected to bind a ligand to produce a biological effect or activity, such as cyclic AMP formation, mobilization of intracellular calcium, or  
15 phosphoinositide metabolism.

#### Polypeptides

P2Y-like GPCR polypeptides according to the invention comprise at least 10, 12, 15,  
20 20, 24, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, or 275 contiguous amino acids selected from the amino acid sequence shown in SEQ ID NO. 2 or a biologically active variant of that sequence, as defined below. A P2Y-like GPCR polypeptide of the invention therefore can be a portion of a P2Y-like GPCR, a full-length P2Y-like GPCR, or a fusion protein comprising all or a portion of a P2Y-like GPCR.

25

#### Biologically Active Variants

P2Y-like GPCR polypeptide variants which are biologically active, *i.e.*, retain the ability to bind a ligand to produce a biological effect, such as cyclic AMP formation,  
30 mobilization of intracellular calcium, or phosphoinositide metabolism, also are P2Y-like GPCR polypeptides. Preferably, naturally or non-naturally occurring P2Y-like

GPCR polypeptide variants have amino acid sequences which are at least about 50, preferably about 75, 90, 96, or 98% identical to an amino acid sequence shown in SEQ ID NO. 2 or a fragment thereof. Percent identity between a putative P2Y-like GPCR polypeptide variant and an amino acid sequence of SEQ ID NO. 2 is  
5 determined using the Blast2 alignment program.

Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid  
10 has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a P2Y-like GPCR polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active P2Y-like GPCR  
15 polypeptide can readily be determined by assaying for binding to a ligand or by conducting a functional assay, as described for example, in the specific Examples, below.  
20

### Fusion Proteins

25 Fusion proteins are useful for generating antibodies against P2Y-like GPCR polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a P2Y-like GPCR polypeptide. Protein affinity chromatography or library-based  
30 assays for protein-protein interactions, such as the yeast two-hybrid or phage display



systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

5 A P2Y-like GPCR polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 10, 12, 15, 20, 24, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, or 275 contiguous amino acids of SEQ ID NO. 2 or a biologically active variant of SEQ ID NO. 2. Contiguous amino acids for use in a fusion protein can be selected from the amino acid sequence shown in SEQ ID NO. 2 or from a biologically active variant of  
10 those sequences, such as those described above. The first polypeptide segment also can comprise full-length P2Y-like G protein-coupled receptor.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include  $\beta$ -galactosidase,  $\beta$ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including  
15 blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lcx a DNA binding domain (DBD) fusions, GAL4 DNA  
20 binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the P2Y-like GPCR polypeptide-encoding sequence and the heterologous protein sequence, so that the P2Y-like GPCR polypeptide can be cleaved and purified away  
25 from the heterologous moiety.

A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by  
30 standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which

- 13 -

comprises coding sequences selected from SEQ ID NO. 1 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI),  
5 Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

#### Identification of Species Homologs

10 Species homologs of human P2Y-like GPCR polypeptide can be obtained using P2Y-like GPCR polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of P2Y-like GPCR  
15 polypeptide, and expressing the cDNAs as is known in the art.

#### Polynucleotides

20 A P2Y-like GPCR polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a P2Y-like GPCR polypeptide. A genomic nucleotide sequence comprising coding sequences for SEQ ID NO. 2 is shown in SEQ ID NO. 1. There are two potential start sites in the genomic sequence. The second start site (bold, underlined ATG in SEQ ID NO. 1) follows the Kozak rule very precisely, while the first potential start site (bold only in  
25 SEQ ID NO. 1) does not perfectly conform to the rule. Splicing sites are conserved in both exons, as indicated by italics in SEQ ID NO. 1. The coding sequences of the two exons are shown in SEQ ID NOS. 4 and 5.

30 Degenerate nucleotide sequences encoding human P2Y-like GPCR polypeptides, as well as homologous nucleotide sequences which are at least about 50, preferably about 75, 90, 96, or 98% identical to a nucleotide sequence shown in SEQ ID NOS.

1, 4, or 5 or its complement also are P2Y-like GPCR polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. Complementary DNA (cDNA) molecules, species homologs, and variants of P2Y-like GPCR polynucleotides which encode biologically active P2Y-like GPCR polypeptides also are P2Y-like GPCR polynucleotides.

Identification of Polynucleotide Variants and Homologs

Variants and homologs of the P2Y-like GPCR polynucleotides described above also are P2Y-like GPCR polynucleotides. Typically, homologous P2Y-like GPCR polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known P2Y-like GPCR polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions—2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50°C once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each—homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

Species homologs of the P2Y-like GPCR polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of P2Y-like GPCR polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the  $T_m$  of a double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner *et al.*, *J. Mol. Biol.* 81, 123 (1973)). Variants of human P2Y-like GPCR polynucleotides or P2Y-like GPCR polynucleotides of other species can therefore be identified by hybridizing a putative homologous P2Y-like GPCR polynucleotide with a poly-

- 15 -

nucleotide having a nucleotide sequence of SEQ ID NO. 1, 4, or 5 or the complement thereof to form a test hybrid. The melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of  
5 basepair mismatches within the test hybrid is calculated.

Nucleotide sequences which hybridize to P2Y-like GPCR polynucleotides or their complements following stringent hybridization and/or wash conditions also are P2Y-like GPCR polynucleotides. Stringent wash conditions are well known and  
10 understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20°C below the  
15 calculated  $T_m$  of the hybrid under study. The  $T_m$  of a hybrid between a P2Y-like GPCR polynucleotide having a nucleotide sequence shown in SEQ ID NO. 1, 4, or 5 or the complement thereof and a polynucleotide sequence which is at least about 50, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, *Proc.*  
20 *Natl. Acad. Sci. U.S.A.* 48, 1390 (1962):

$$T_m = 81.5^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l,$$

where  $l$  = the length of the hybrid in basepairs.

25 Stringent wash conditions include, for example, 4X SSC at 65°C, or 50% formamide, 4X SSC at 42°C, or 0.5X SSC, 0.1% SDS at 65°C. Highly stringent wash conditions include, for example, 0.2X SSC at 65°C.

### Preparation of Polynucleotides

A P2Y-like GPCR polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by  
5 a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated P2Y-like GPCR polynucleotides. For example, restriction  
10 enzymes and probes can be used to isolate polynucleotide fragments which comprises P2Y-like GPCR nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

P2Y-like GPCR cDNA molecules can be made with standard molecular biology  
15 techniques, using P2Y-like GPCR mRNA as a template. P2Y-like GPCR cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

20 Alternatively, synthetic chemistry techniques can be used to synthesize P2Y-like GPCR polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a P2Y-like GPCR polypeptide having, for example, the amino acid sequence shown in SEQ ID NO. 2  
25 or a biologically active variant thereof.

### Extending Polynucleotides

Various PCR-based methods can be used to extend the nucleic acid sequences  
30 encoding the disclosed portions of human P2Y-like GPCR polypeptide to detect upstream sequences such as promoters and regulatory elements. For example,

restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Applic.* 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res.* 16, 8186, 1988). Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic.* 1, 111-119, 1991). In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res.* 19, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo  
5 d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For  
10 example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the  
15 entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

#### 20 Obtaining Polypeptides

P2Y-like GPCR polypeptides can be obtained, for example, by purification from cells, by expression of P2Y-like GPCR polynucleotides, or by direct chemical  
synthesis.

25

#### Protein Purification

P2Y-like GPCR polypeptides can be purified from any human cell which expresses the receptor, including host cells which have been transfected with P2Y-like GPCR  
30 polynucleotides which express such polypeptides. A purified P2Y-like GPCR polypeptide is separated from other compounds which normally associate with the

P2Y-like GPCR polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

A P2Y-like GPCR polypeptide can be conveniently isolated as a complex with its associated G protein, as described in the specific examples, below. A preparation of purified P2Y-like GPCR polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

#### Expression of Polynucleotides

To express a P2Y-like GPCR polypeptide, a P2Y-like GPCR polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding P2Y-like GPCR polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding a P2Y-like GPCR polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g.,



cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.

5 The control elements or regulatory sequences are those non-translated regions of the vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in  
10 bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses  
15 (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a P2Y-like GPCR polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

20

#### Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the P2Y-like GPCR polypeptide. For example, when a large  
25 quantity of a P2Y-like GPCR polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the P2Y-like GPCR polypeptide can be  
30 ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced. pIN

vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol.* 153, 516-544, 1987.

#### Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding P2Y-like GPCR polypeptides can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6, 307-311, 1987). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J.* 3, 1671-1680, 1984; Broglie *et al.*, *Science* 224, 838-843, 1984; Winter *et al.*, *Results Probl. Cell Differ.* 17, 85-105, 1991). These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews-(*e.g.*, Hobbs or Murray, in MCGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, N.Y., pp. 191-196, 1992).

An insect system also can be used to express a P2Y-like GPCR polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus

(AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding P2Y-like GPCR polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of P2Y-like GPCR polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which P2Y-like GPCR polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994).

#### Mammalian Expression Systems

A number of viral-based expression systems can be used to express P2Y-like GPCR polypeptides in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding P2Y-like GPCR polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a P2Y-like GPCR polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci.* 81, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles).

Specific initiation signals also can be used to achieve more efficient translation of sequences encoding P2Y-like GPCR polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a P2Y-

like GPCR polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ.* 20, 125-162, 1994).

#### Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed P2Y-like GPCR polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (*e.g.*, CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express P2Y-like GPCR polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a

selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced P2Y-like GPCR sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.

Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell* 22, 817-23, 1980) genes which can be employed in *tk* or *aprf* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci.* 77, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-51, 1988). Visible markers such as anthocyanins,  $\beta$ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55, 121-131, 1995).

#### Detecting Expression of Polypeptides

Although the presence of marker gene expression suggests that the P2Y-like GPCR polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a P2Y-like GPCR polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode a P2Y-like GPCR polypeptide can be identified by the absence of marker gene

function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a P2Y-like GPCR polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the P2Y-like GPCR polynucleotide.

5

Alternatively, host cells which contain a P2Y-like GPCR polynucleotide and which express a P2Y-like GPCR polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a P2Y-like GPCR polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a P2Y-like GPCR polypeptide. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a P2Y-like GPCR polypeptide to detect transformants which contain a P2Y-like GPCR polynucleotide.

A variety of protocols for detecting and measuring the expression of a P2Y-like GPCR polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a P2Y-like GPCR polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med.* 158, 1211-1216, 1983).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for

30

- 26 -

producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding P2Y-like GPCR polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a P2Y-like GPCR polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

#### Expression and Purification of Polypeptides

Host cells transformed with nucleotide sequences encoding a P2Y-like GPCR polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode P2Y-like GPCR polypeptides can be designed to contain signal sequences which direct secretion of soluble P2Y-like GPCR polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound P2Y-like GPCR polypeptide.

As discussed above, other constructions can be used to join a sequence encoding a P2Y-like GPCR polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain

- 27 -

utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the P2Y-like GPCR polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a P2Y-like GPCR polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in Porath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means for purifying the P2Y-like GPCR polypeptide from the fusion protein. Vectors which contain fusion proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

#### Chemical Synthesis

Sequences encoding a P2Y-like GPCR polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al.*, *Nucl. Acids Res. Symp. Ser.* 225-232, 1980). Alternatively, a P2Y-like GPCR polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963; Roberge *et al.*, *Science* 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of P2Y-like GPCR polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (*e.g.*, Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH Freeman and Co., New York, N.Y., 1983). The



composition of a synthetic P2Y-like GPCR polypeptide can be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; *see* Creighton, *supra*). Additionally, any portion of the amino acid sequence of the P2Y-like GPCR polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

#### Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce P2Y-like GPCR polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter P2Y-like GPCR polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

#### Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of a P2Y-like GPCR polypeptide. "Antibody" as used herein includes intact

immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv, which are capable of binding an epitope of a P2Y-like GPCR polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require  
5 more, *e.g.*, at least 15, 25, or 50 amino acids.

An antibody which specifically binds to an epitope of a P2Y-like GPCR polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immuno-  
10 precipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the  
15 immunogen.

Typically, an antibody which specifically binds to a P2Y-like GPCR polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably,  
20 antibodies which specifically bind to P2Y-like GPCR polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a P2Y-like GPCR polypeptide from solution.

P2Y-like GPCR polypeptides can be used to immunize a mammal, such as a mouse,  
25 rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a P2Y-like GPCR polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral  
30 gels (*e.g.*, aluminum hydroxide), and surface active substances (*e.g.* lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin,

and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

5 Monoclonal antibodies which specifically bind to a P2Y-like GPCR polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature* 256, 495-497, 1985; Kozbor *et al.*, *J. Immunol. Methods* 81, 31-42, 1985; Cote *et al.*, *Proc. Natl. Acad. Sci.* 80, 2026-10 2030, 1983; Cole *et al.*, *Mol. Cell Biol.* 62, 109-120, 1984).

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, 15 *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger *et al.*, *Nature* 312, 604-608, 1984; Takeda *et al.*, *Nature* 314, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or 20 may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grafting of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in 25 GB2188638B. Antibodies which specifically bind to a P2Y-like GPCR polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can 30 be adapted using methods known in the art to produce single chain antibodies which specifically bind to P2Y-like GPCR polypeptides. Antibodies with related

specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, *Proc. Natl. Acad. Sci.* 88, 11120-23, 1991).

- 5 Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J. Cancer Prev.* 5, 507-11). Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol.* 15,  
10 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in Mallender & Voss, 1994, *J. Biol. Chem.* 269, 199-206.

- A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using  
15 standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*, 1995, *Int. J. Cancer* 61, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91).

- 20 Antibodies which specifically bind to P2Y-like GPCR polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci.* 86, 3833-3837, 1989;  
25 Winter *et al.*, *Nature* 349, 293-299, 1991).

- Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and  
30 which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a P2Y-like GPCR polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

#### Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of P2Y-like GPCR gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, *Meth. Mol. Biol.* 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol.* 26, 1-72, 1994; Uhlmann *et al.*, *Chem. Rev.* 90, 543-583, 1990.

Modifications of P2Y-like GPCR gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the P2Y-like GPCR. Oligonucleotides derived from the transcription

- 33 -

initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (e.g., Gee *et al.*, in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a P2Y-like GPCR polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a P2Y-like GPCR polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent P2Y-like GPCR nucleotides, can provide sufficient targeting specificity for P2Y-like GPCR mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular P2Y-like GPCR polynucleotide sequence.

Antisense oligonucleotides can be modified without affecting their ability to hybridize to a P2Y-like GPCR polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group

are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal *et al.*, *Trends Biotechnol.* 10, 152-158, 1992; Uhlmann *et al.*, *Chem. Rev.* 90, 543-584, 1990; Uhlmann *et al.*, *Tetrahedron. Lett.* 215, 3539-3542, 1987.

5

### Ribozymes

Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, *Science* 236, 1532-1539; 1987; Cech, *Ann. Rev. Biochem.* 59, 543-568; 1990, Cech, *Curr. Opin. Struct. Biol.* 2, 605-609; 1992, Couture & Stinchcomb, *Trends Genet.* 12, 510-515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff *et al.*, U.S. Patent 5,641,673). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

The coding sequence of a P2Y-like GPCR polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from the P2Y-like GPCR polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff *et al.* *Nature* 334, 585-591, 1988). For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach *et al.*, EP 321,201).

Specific ribozyme cleavage sites within a P2Y-like GPCR RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA

sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate P2Y-like GPCR RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease P2Y-like GPCR expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

#### Screening Methods

The invention provides assays for screening test compounds which bind to or modulate the activity of a P2Y-like GPCR polypeptide or a P2Y-like GPCR



- 36 -

polynucleotide. A test compound preferably binds to a P2Y-like GPCR polypeptide or polynucleotide. More preferably, a test compound decreases or increases a biological effect mediated via human P2Y-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

#### Differentially Expressed Genes

Described herein are methods for the identification of genes whose products interact with human P2Y-like GPCR polypeptide. Such genes may represent genes that are differentially expressed in disorders including, but not limited to, CNS disorders, cardiovascular disorders, asthma, osteoporosis, diabetes, and chronic obstructive pulmonary disease (COPD). Further, such genes may represent genes that are differentially regulated in response to manipulations relevant to the progression or treatment of such diseases. Additionally, such genes may have a temporally modulated expression, increased or decreased at different stages of tissue or organism development. A differentially expressed gene may also have its expression modulated under control versus experimental conditions. In addition, the human P2Y-like GPCR polypeptide gene or gene product may itself be tested for differential expression.

The degree to which expression differs in a normal versus a diseased state need only be large enough to be visualized via standard characterization techniques such as differential display techniques. Other such standard characterization techniques by which expression differences may be visualized include but are not limited to, quantitative RT (reverse transcriptase), PCR, and Northern analysis.

#### Identification of Differentially Expressed Genes

To identify differentially expressed genes total RNA or, preferably, mRNA is isolated from tissues of interest. For example, RNA samples are obtained from

tissues of experimental subjects and from corresponding tissues of control subjects. Any RNA isolation technique that does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Ausubel *et al.*, ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc.  
5 New York, 1987-1993. Large numbers of tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, U.S. Patent 4,843,155.

Transcripts within the collected RNA samples that represent RNA produced by  
10 differentially expressed genes are identified by methods well known to those of skill in the art. They include, for example, differential screening (Tedder *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 85, 208-12, 1988), subtractive hybridization (Hedrick *et al.*, *Nature* 308, 149-53; Lee *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88, 2825, 1984), preferably, differential display (Liang & Pardee, *Science* 257, 967-71, 1992; U.S.  
15 Patent 5,262,311), and microarrays.

The differential expression information may itself suggest relevant methods for the treatment of disorders involving the human P2Y-like GPCR polypeptide. For example, treatment may include a modulation of expression of the differentially  
20 expressed genes and/or the gene encoding the human P2Y-like GPCR polypeptide. The differential expression information may indicate whether the expression or activity of the differentially expressed gene or gene product or the human P2Y-like GPCR polypeptide gene or gene product are up-regulated or down-regulated.

## 25 Test Compounds

Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be  
30 isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, test

compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound" library method, and  
5 synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, *Anticancer Drug Des.* 12, 145, 1997.

10 Methods for the synthesis of molecular libraries are well known in the art (see, for example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90, 6909, 1993; Erb *et al.* *Proc. Natl. Acad. Sci. U.S.A.* 91, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem.* 37, 2678, 1994; Cho *et al.*, *Science* 261, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2061; Gallop *et al.*, *J.*  
15 *Med. Chem.* 37, 1233, 1994). Libraries of compounds can be presented in solution (see, e.g., Houghten, *BioTechniques* 13, 412-421, 1992), or on beads (Lam, *Nature* 354, 82-84, 1991), chips (Fodor, *Nature* 364, 555-556, 1993), bacteria or spores (Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89, 1865-1869, 1992), or phage (Scott & Smith, *Science* 249, 386-390, 1990; Devlin,  
20 *Science* 249, 404-406, 1990); Cwirla *et al.*, *Proc. Natl. Acad. Sci.* 97, 6378-6382, 1990; Felici, *J. Mol. Biol.* 222, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

#### High Throughput Screening

25 Test compounds can be screened for the ability to bind to P2Y-like GPCR polypeptides or polynucleotides or to affect P2Y-like GPCR activity or P2Y-like GPCR gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques  
30 utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500  $\mu$ l. In addition to the plates, many

instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.

Alternatively, "free format assays," or assays that have no physical barrier between  
5 samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 19, 1614-18 (1994). The cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially  
10 released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

Another example of a free format assay is described by Chelsky, "Strategies for  
15 Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying  
20 combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

Yet another example is described by Salmon *et al.*, *Molecular Diversity* 2, 57-63  
25 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

Another high throughput screening method is described in Beutel *et al.*, U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more  
30 assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.

When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

### Binding Assays

5

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of the P2Y-like GPCR polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small  
10 peptides or peptide-like molecules. Potential ligands which may bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known GPCRs and analogues or derivatives thereof. Natural ligands of GPCRs include adrenomedullin, amylin, calcitonin gene related protein (CGRP), calcitonin, anandamide, serotonin, histamine, adrenalin, noradrenalin, platelet activating factor,  
15 thrombin, C5a, bradykinin, and chemokines.

In binding assays, either the test compound or the P2Y-like GPCR polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or  
20 luciferase. Detection of a test compound which is bound to the P2Y-like GPCR polypeptide can then be accomplished, for example, by direct counting of radioemission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

25 Alternatively, binding of a test compound to a P2Y-like GPCR polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a P2Y-like GPCR polypeptide. A microphysiometer (e.g., Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-  
30 addressable potentiometric sensor (LAPS). Changes in this acidification rate can be

used as an indicator of the interaction between a test compound and a P2Y-like GPCR polypeptide (McConnell *et al.*, *Science* 257, 1906-1912, 1992).

Determining the ability of a test compound to bind to a P2Y-like GPCR polypeptide  
5 also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem.* 63, 2338-2345, 1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5, 699-705, 1995). BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface  
10 plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a P2Y-like GPCR polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent  
15 5,283,317; Zervos *et al.*, *Cell* 72, 223-232, 1993; Madura *et al.*, *J. Biol. Chem.* 268, 12046-12054, 1993; Bartel *et al.*, *BioTechniques* 14, 920-924, 1993; Iwabuchi *et al.*, *Oncogene* 8, 1693-1696, 1993; and Brent W094/10300), to identify other proteins which bind to or interact with the P2Y-like GPCR polypeptide and modulate its activity.

20 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding a P2Y-like GPCR polypeptide can be fused to a polynucleotide encoding  
25 the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the  
30 transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a

transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the P2Y-like GPCR polypeptide.

5

It may be desirable to immobilize either the P2Y-like GPCR polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the P2Y-like GPCR polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the P2Y-like GPCR polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a P2Y-like GPCR polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

10  
15  
20

In one embodiment, the P2Y-like GPCR polypeptide is a fusion protein comprising a domain that allows the P2Y-like GPCR polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed P2Y-like GPCR polypeptide; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined

25  
30

either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also  
5 can be used in the screening assays of the invention. For example, either a P2Y-like  
GPCR polypeptide (or polynucleotide) or a test compound can be immobilized  
utilizing conjugation of biotin and streptavidin. Biotinylated P2Y-like GPCR  
polypeptides (or polynucleotides) or test compounds can be prepared from biotin-  
10 NHS(N-hydroxysuccinimide) using techniques well known in the art (e.g.,  
biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of  
streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which  
specifically bind to a P2Y-like GPCR polypeptide, polynucleotide, or a test  
compound, but which do not interfere with a desired binding site, such as the active  
15 site of the P2Y-like GPCR polypeptide, can be derivatized to the wells of the plate.  
Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the  
GST-immobilized complexes, include immunodetection of complexes using anti-  
bodies which specifically bind to the P2Y-like GPCR polypeptide or test compound,  
20 enzyme-linked assays which rely on detecting an activity of the P2Y-like GPCR  
polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a P2Y-like GPCR polypeptide or  
polynucleotide also can be carried out in an intact cell. Any cell which comprises a  
25 P2Y-like GPCR polypeptide or polynucleotide can be used in a cell-based assay  
system. A P2Y-like GPCR polynucleotide can be naturally occurring in the cell or  
can be introduced using techniques such as those described above. Binding of the  
test compound to a P2Y-like GPCR polypeptide or polynucleotide is determined as  
described above.



### Functional Assays

Test compounds can be tested for the ability to increase or decrease a biological effect of a P2Y-like GPCR polypeptide. Such biological effects can be determined using the functional assays described in the specific examples, below. Functional assays can be carried out after contacting either a purified P2Y-like GPCR polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases a functional activity of a P2Y-like GPCR by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for decreasing P2Y-like GPCR activity. A test compound which increases P2Y-like GPCR activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for increasing P2Y-like GPCR activity.

One such screening procedure involves the use of melanophores which are transfected to express a P2Y-like GPCR polypeptide. Such a screening technique is described in WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide by contacting the melanophore cells which comprise the receptor with both a receptor ligand and a test compound to be screened. Inhibition of the signal generated by the ligand indicates that a test compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be employed for identifying a test compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each test compound generates a signal, *i.e.*, activates the receptor.

Other screening techniques include the use of cells which express a human P2Y-like GPCR polypeptide (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation (*see, e.g., Science* 246, 181-296, 1989). For example, test compounds may be contacted with a cell which expresses a human P2Y-like GPCR polypeptide and a second messenger response,

e.g., signal transduction or pH changes, can be measured to determine whether the test compound activates or inhibits the receptor.

Another such screening technique involves introducing RNA encoding a human P2Y-like GPCR polypeptide into *Xenopus* oocytes to transiently express the receptor. The transfected oocytes can then be contacted with the receptor ligand and a test compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for test compounds which are thought to inhibit activation of the receptor.

Another screening technique involves expressing a human P2Y-like GPCR polypeptide in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

Details of functional assays such as those described above are provided in the specific examples, below.

#### Gene Expression

In another embodiment, test compounds which increase or decrease P2Y-like GPCR gene expression are identified. A P2Y-like GPCR polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the P2Y-like GPCR polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively,

when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

- 5 The level of P2Y-like GPCR mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a P2Y-like GPCR polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as
- 10 radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labeled amino acids into a P2Y-like GPCR polypeptide.
- 15 Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses a P2Y-like GPCR polynucleotide can be used in a cell-based assay system. The P2Y-like GPCR polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, such as CHO or human
- 20 embryonic kidney 293 cells, can be used.

#### Pharmaceutical Compositions

- The invention also provides pharmaceutical compositions which can be administered
- 25 to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a P2Y-like GPCR polypeptide, P2Y-like GPCR polynucleotide, antibodies which specifically bind to a P2Y-like GPCR polypeptide, or mimetics, agonists, antagonists, or inhibitors of a P2Y-like GPCR polypeptide activity. The compositions can be administered alone or in combination with at least
- 30 one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline,

buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

In addition to the active ingredients, these pharmaceutical compositions can contain  
5 suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries  
which facilitate processing of the active compounds into preparations which can be  
used pharmaceutically. Pharmaceutical compositions of the invention can be  
administered by any number of routes including, but not limited to, oral, intravenous,  
intramuscular, intra-arterial, intramedullary, intrapulmonary, intrahepatic, intrathecal,  
10 intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral,  
topical, sublingual, or rectal means. Pharmaceutical compositions for oral admini-  
stration can be formulated using pharmaceutically acceptable carriers well known in  
the art in dosages suitable for oral administration. Such carriers enable the  
pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules,  
15 liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.  
Pharmaceutical preparations for oral use can be obtained through combination of  
active compounds with solid excipient, optionally grinding a resulting mixture, and  
processing the mixture of granules, after adding suitable auxiliaries, if desired, to  
obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers,  
20 such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn,  
wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxy-  
propylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic  
and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating  
or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone,  
25 agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated  
sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone,  
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and  
30 suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to

the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

5      Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid  
10     polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection  
15     suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.  
20     Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally  
25     known in the art.

The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or  
30     lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric,

acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH  
5 range of 4.5 to 5.5, that is combined with buffer prior to use.

Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be  
10 placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

#### Therapeutic Indications and Methods

15 GPCRs are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies, including COPD, CNS disorders, cancer, cardiovascular disorders, osteoporosis, diabetes, asthma, and obesity. Accordingly, it is desirable to find compounds and drugs which stimulate a GPCR on  
20 the one hand and which can inhibit the function of a GPCR on the other hand. For example, compounds which activate a GPCR may be employed for therapeutic purposes, such as the treatment of asthma, inflammation, CNS disorders, including Parkinson's disease, acute heart failure, urinary retention, and osteoporosis. In particular, compounds which activate GPCRs are useful in treating various  
25 cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion. Regulation of human P2Y-like GPCR may be particularly  
30 useful in conditions in which alterations in neuromodulation are desired.

In general, compounds which inhibit activation of a GPCR can be used for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, inflammation, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as Huntington's disease or Tourett's syndrome, among others. Compounds which inhibit GPCRs also are useful in reversing endogenous anorexia and in the control of bulimia.

10 COPD. Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of emphysema and peripheral airway obstruction due to chronic bronchitis (Senior & Shapiro, *Pulmonary Diseases and Disorders*, 3d ed., New York, McGraw-Hill, 1998, pp. 659-681, 1998; Barnes, *Chest* 117, 10S-14S, 2000). Emphysema is characterized  
15 by destruction of alveolar walls leading to abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of two successive years. In COPD, airflow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although  
20 the disease does occur in non-smokers.

Chronic inflammation of the airways is a key pathological feature of COPD (Senior & Shapiro, 1998). The inflammatory cell population comprises increased numbers of macrophages, neutrophils, and CD8<sup>+</sup> lymphocytes. Inhaled irritants, such as  
25 cigarette smoke, activate macrophages which are resident in the respiratory tract, as well as epithelial cells leading to release of chemokines (e.g., interleukin-8) and other chemotactic factors. These chemotactic factors act to increase the neutrophil/-monocyte trafficking from the blood into the lung tissue and airways. Neutrophils and monocytes recruited into the airways can release a variety of potentially  
30 damaging mediators such as proteolytic enzymes and reactive oxygen species. Matrix degradation and emphysema, along with airway wall thickening, surfactant

dysfunction, and mucus hypersecretion, all are potential sequelae of this inflammatory response that lead to impaired airflow and gas exchange.

Several GPCRs have been implicated in the pathology of COPD. For example, the chemokine IL-8 acts through CXCR1 and CXCR2, and antagonists for these receptors are under investigation as therapeutics for COPD. Members of the P2Y family of metabotropic receptors may play key roles in normal pulmonary function. In particular, the P2Y<sub>2</sub> receptor is believed to be involved in the regulation of mucociliary clearance mechanisms in the lung, and agonists of this receptor may stimulate airway mucus clearance in patients with chronic bronchitis (Yerxa Johnson, *Drugs of the Future* 24, 759-769, 1999). GPCRs, therefore, are therapeutic targets for COPD, and the identification of additional members of existing GPCR families or of novel GPCRs would yield further attractive targets.

Obesity. Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat. Obesity is associated with important medical morbidities and an increase in mortality. The causes of obesity are poorly understood and may be due to genetic factors, environmental factors or a combination of the two to cause a positive energy balance. In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss. Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that either increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia and wasting disorders.

This gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases



in satiety, modulation of body weight, and/or other eating disorders such as bulimia. Also this gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity/overweight-associated comorbidities including hypertension, type 2 diabetes, coronary artery disease, hyperlipidemia, stroke, gallbladder disease, gout, osteoarthritis, sleep apnea and respiratory problems, some types of cancer including endometrial, breast, prostate, and colon cancer, thrombotic disease, polycystic ovarian syndrome, reduced fertility, complications of pregnancy, menstrual irregularities, hirsutism, stress incontinence, and depression.

10

Diabetes. Treatment of diabetes with regulators of P2Y-like GPCR activity is of particular interest. Diabetes mellitus is a common metabolic disorder characterized by an abnormal elevation in blood glucose, alterations in lipids and abnormalities (complications) in the cardiovascular system, eye, kidney and nervous system. Diabetes is divided into two separate diseases: type 1 diabetes (juvenile onset) that results from a loss of cells which make and secrete insulin, and type 2 diabetes (adult onset) which is caused by a defect in insulin secretion and a defect in insulin action.

15

20

Type 1 diabetes is initiated by an autoimmune reaction that attacks the insulin secreting cells (beta cells) in the pancreatic islets. Agents that prevent this reaction from occurring or that stop the reaction before destruction of the beta cells has been accomplished are potential therapies for this disease. Other agents that induce beta cell proliferation and regeneration are also potential therapies.

25

Type II diabetes is the most common of the two diabetic conditions (6% of the population). The defect in insulin secretion is an important cause of the diabetic condition and results from an inability of the beta cell to properly detect and respond to rises in blood glucose levels with insulin release. Therapies that increase the response by the beta cell to glucose would offer an important new treatment for this disease.

30

The defect in insulin action in Type II diabetic subjects is another target for therapeutic intervention. Agents that increase the activity of the insulin receptor in muscle, liver and fat will cause a decrease in blood glucose and a normalization of plasma lipids. The receptor activity can be increased by agents that directly stimulate  
5 the receptor or that increase the intracellular signals from the receptor. Other therapies can directly activate the cellular end process, i.e. glucose transport or various enzyme systems, to generate an insulin-like effect and therefore a produce beneficial outcome. Because overweight subjects have a greater susceptibility to Type II diabetes, any agent that reduces body weight is a possible therapy.

10

Both Type I and Type diabetes can be treated with agents that mimic insulin action or that treat diabetic complications by reducing blood glucose levels. Likewise agents that reduces new blood vessel growth can be used to treat the eye complications that develop in both diseases.

15

Cancer. Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counterparts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal deathinducing  
20 signals (immortalization), increased cellular motility and invasiveness, increased ability to recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these aberrant physiologies, along with the acquisition of drug-resistance frequently lead to an intractable disease state in which organ failure  
25 and patient death ultimately ensue.

Most standard cancer therapies target cellular proliferation and rely on the differential proliferative capacities between transformed and normal cells for their efficacy. This approach is hindered by the facts that several important normal cell  
30 types are also highly proliferative and that cancer cells frequently become resistant to

these agents. Thus, the therapeutic indices for traditional anti-cancer therapies rarely exceed 2.0.

5 The advent of genomics-driven molecular target identification has opened up the possibility of identifying new cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients. Thus, newly discovered tumor-associated genes and their products can be tested for their role(s) in disease and used as tools to discover and develop innovative therapies. Genes playing important roles in any of the physiological processes outlined above can be  
10 characterized as cancer targets.

Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized *in vitro* for their biochemical properties and then  
15 used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities. Activators and/or inhibitors of target protein activity can be identified in this manner and subsequently tested in cellular and *in vivo* disease models for anti-cancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and  
20 toxicological analyses form the basis for drug development and subsequent testing in humans.

Asthma. Allergy is a complex process in which environmental antigens induce clinically adverse reactions. The inducing antigens, called allergens, typically elicit a  
25 specific IgE response and, although in most cases the allergens themselves have little or no intrinsic toxicity, they induce pathology when the IgE response in turn elicits an IgE-dependent or T cell-dependent hypersensitivity reaction. Hypersensitivity reactions can be local or systemic and typically occur within minutes of allergen exposure in individuals who have previously been sensitized to an allergen. The  
30 hypersensitivity reaction of allergy develops when the allergen is recognized by IgE antibodies bound to specific receptors on the surface of effector cells, such as mast

cells, basophils, or eosinophils, which causes the activation of the effector cells and the release of mediators that produce the acute signs and symptoms of the reactions. Allergic diseases include asthma, allergic rhinitis (hay fever), atopic dermatitis, and anaphylaxis.

5

Asthma is thought to arise as a result of interactions between multiple genetic and environmental factors and is characterized by three major features: 1) intermittent and reversible airway obstruction caused by bronchoconstriction, increased mucus production, and thickening of the walls of the airways that leads to a narrowing of the  
10 airways, 2) airway hyper-responsiveness caused by a decreased control of airway caliber, and 3) airway inflammation. Certain cells are critical to the inflammatory reaction of asthma and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells, basophils, eosinophils, and other cells that bind IgE. These effector cells accumulate at the site of allergic reaction in the airways and  
15 release toxic products that contribute to the acute pathology and eventually to the tissue destruction related to the disorder. Other resident cells, such as smooth muscle cells, lung epithelial cells, mucus-producing cells, and nerve cells may also be abnormal in individuals with asthma and may contribute to the pathology. While the airway obstruction of asthma, presenting clinically as an intermittent wheeze and  
20 shortness of breath, is generally the most pressing symptom of the disease requiring immediate treatment, the inflammation and tissue destruction associated with the disease can lead to irreversible changes that eventually make asthma a chronic disabling disorder requiring long-term management.

25

Despite recent important advances in our understanding of the pathophysiology of asthma, the disease appears to be increasing in prevalence and severity (Gergen and Weiss, *Am. Rev. Respir. Dis.* 146, 823-24, 1992). It is estimated that 30-40% of the population suffer with atopic allergy, and 15% of children and 5% of adults in the population suffer from asthma (Gergen and Weiss, 1992). Thus, an enormous burden  
30 is placed on our health care resources. However, both diagnosis and treatment of asthma are difficult. The severity of lung tissue inflammation is not easy to measure

and the symptoms of the disease are often indistinguishable from those of respiratory infections, chronic respiratory inflammatory disorders, allergic rhinitis, or other respiratory disorders. Often, the inciting allergen cannot be determined, making removal of the causative environmental agent difficult. Current pharmacological treatments suffer their own set of disadvantages. Commonly used therapeutic agents, such as beta activators, can act as symptom relievers to transiently improve pulmonary function, but do not affect the underlying inflammation. Agents that can reduce the underlying inflammation, such as anti-inflammatory steroids, can have major drawbacks that range from immunosuppression to bone loss (Goodman and Gilman's THE PHARMACOLOGIC BASIS OF THERAPEUTICS, Seventh Edition, MacMillan Publishing Company, NY, USA, 1985). In addition, many of the present therapies, such as inhaled corticosteroids, are short-lasting, inconvenient to use, and must be used often on a regular basis, in some cases for life, making failure of patients to comply with the treatment a major problem and thereby reducing their effectiveness as a treatment.

Because of the problems associated with conventional therapies, alternative treatment strategies have been evaluated. Glycophorin A (Chu and Sharom, *Cell. Immunol.* 145, 223-39, 1992), cyclosporin (Alexander *et al.*, *Lancet* 339, 324-28, 1992), and a nonapeptide fragment of IL-2 (Zav'yalov *et al.*, *Immunol. Lett.* 31, 285-88, 1992) all inhibit interleukin-2 dependent T lymphocyte proliferation; however, they are known to have many other effects. For example, cyclosporin is used as an immunosuppressant after organ transplantation. While these agents may represent alternatives to steroids in the treatment of asthmatics, they inhibit interleukin-2 dependent T lymphocyte proliferation and potentially critical immune functions associated with homeostasis. Other treatments that block the release or activity of mediators of bronchoconstriction, such as cromones or anti-leukotrienes, have recently been introduced for the treatment of mild asthma, but they are expensive and not effective in all patients and it is unclear whether they have any effect on the chronic changes associated with asthmatic inflammation. What is needed in the art is the identification of a treatment that can act in pathways critical to the development

of asthma that both blocks the episodic attacks of the disorder and preferentially dampens the hyperactive allergic immune response without immunocompromising the patient.

5     GPCRs and asthma

GPCRs interact with heterotrimeric guanine nucleotide binding regulatory proteins (G proteins) that modulate a variety of second messenger systems or ionic conductances to effect physiological responses. Many of the mediators involved in  
10     airway smooth muscle contraction and in the chemoattraction of inflammatory cells exert their effects through GPCR binding. Among the mediators of smooth muscle contraction are leukotrienes, platelet-activating factor, endothelin-1, adenosine, and thromboxane A<sub>2</sub>. Receptor inhibitors that block the activation of GPCRs by some of these mediators have been successfully used as treatments for asthma. Among the  
15     chemoattractants of inflammatory cells are the chemokines, such as eotaxin, MCP-4, RANTES, and IL-8. Chemokine receptor inhibitors similarly are being developed as treatments for asthma. Sarau *et al.*, *Mol. Pharmacol.* 56, 657-63, 1999; Kitaura *et al.*, *J. Biol. Chem.* 271, 7725-30, 1996; Liggett *et al.*, *Am. J. Respir. Crit. Care Med.* 152, 394-402, 1995; Panettieri *et al.*, *J. Immunol.* 154, 2358-65, 1995; Noveral *et al.*,  
20     *Am. J. Physiol.* 263, L317-24, 1992; Honda *et al.*, *Nature* 349, 342-46, 1991.

Activation of some GPCRs may conversely have beneficial effects in asthma. For example, receptor activators that activate the  $\beta$ 1- and  $\beta$ 2-adrenergic GPCRs are used therapeutically to relax contracted airway smooth muscle in the treatment of asthma  
25     attacks. Thus, regulation of GPCRs in either a positive or negative manner may play an important role in the treatment of asthma.

Osteoporosis. Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility  
30     and a consequent increase in fracture risk. It is the most common human metabolic bone disorder. Established osteoporosis includes the presence of fractures. Bone

turnover occurs by the action of two major effector cell types within bone: the osteoclast, which is responsible for bone resorption, and the osteoblast, which synthesizes and mineralizes bone matrix. The actions of osteoclasts and osteoblasts are highly co-ordinated. Osteoclast precursors are recruited to the site of turnover; they differentiate and fuse to form mature osteoclasts which then resorb bone. Attached to the bone surface, osteoclasts produce an acidic microenvironment in a tightly defined junction between the specialized osteoclast border membrane and the bone matrix, thus allowing the localized solubilization of bone matrix. This in turn facilitates the proteolysis of demineralized bone collagen. Matrix degradation is thought to release matrix-associated growth factor and cytokines, which recruit osteoblasts in a temporally and spatially controlled fashion. Osteoblasts synthesize and secrete new bone matrix proteins, and subsequently mineralize this new matrix. In the normal skeleton this is a physiological process which does not result in a net change in bone mass. In pathological states, such as osteoporosis, the balance between resorption and formation is altered such that bone loss occurs. See WO 99/45923.

The osteoclast itself is the direct or indirect target of all currently available osteoporosis agents with the possible exception of fluoride. Antiresorptive therapy prevents further bone loss in treated individuals. Osteoblasts are derived from multipotent stem cells that reside in bone marrow and also gives rise to adipocytes, chondrocytes, fibroblasts and muscle cells. Selective enhancement of osteoblast activity is a highly desirable goal for osteoporosis therapy since it would result in an increase in bone mass, rather than a prevention of further bone loss. An effective anabolic therapy would be expected to lead to a significantly greater reduction in fracture risk than currently available treatments.

The activators or inhibitors to the newly discovered polypeptides may act as antiresorptive by directly altering the osteoclast differentiation, osteoclast adhesion to the bone matrix or osteoclast function of degrading the bone matrix. The activators or inhibitors could indirectly alter the osteoclast function by interfering in the

- 59 -

synthesis and/or modification of effector molecules of osteoclast differentiation or function such as cytokines, peptide or steroid hormones, proteases, etc.

5 The activators or inhibitors to the newly discovered polypeptides may act as anabolics by directly enhancing the osteoblast differentiation and /or its bone matrix forming function. The activators or inhibitors could also indirectly alter the osteoblast function by enhancing the synthesis of growth factors, peptide or steroid hormones or decreasing the synthesis of inhibitory molecules.

10 The activators and inhibitors may be used to mimic, augment or inhibit the action of the newly discovered polypeptides which may be useful to treat osteoporosis, Paget's disease, degradation of bone implants particularly dental implants.

Cardiovascular Diseases. Cardiovascular diseases include the following disorders  
15 of the heart and the vascular system: congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, and peripheral vascular diseases.

20 Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure, such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

25 Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included, as well as the acute treatment of MI and the prevention of complications.

30 Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen.



This group of diseases includes stable angina, unstable angina, and asymptomatic ischemia.

5 Arrhythmias include all forms of atrial and ventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, and ventricular fibrillation), as well as bradycardic forms of arrhythmias.

10 Vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others). The disclosed gene and its product may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications. Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic  
15 peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon, and venous disorders.

Disorders of the nervous system. P2Y-like receptors can be regulated to treat  
20 disorders of the nervous system. Disorders of the nervous system which may be treated include brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, including ALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke, post-traumatic brain injury, and small-vessel cerebrovascular disease. Dementias,  
25 such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism linked to chromosome 17, frontotemporal dementias, including Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff's psychosis  
30 also can be treated. Similarly, it may be possible to treat cognitive-related disorders, such as mild cognitive impairment, age-associated memory impairment, age-related

cognitive decline, vascular cognitive impairment, attention deficit disorders, attention deficit hyperactivity disorders, and memory disturbances in children with learning disabilities, by regulating the activity of P2Y-like receptors.

5 Pain that is associated with nervous system disorders also can be treated by regulating the activity of P2Y-like receptors. Pain which can be treated includes that associated with central nervous system disorders, such as multiple sclerosis, spinal  
10 cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, reflex sympathetic dystrophy (RSD), trigeminal neuralgia, radioculopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy) vasculitic neuropathy (e.g. secondary to connective tissue disease), paraneoplastic poly-  
15 neuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, and post-herpetic neuralgia. Pain associated with cancer and cancer treatment also can be treated, as can headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache,  
20 cluster headache, and chronic paroxysmal hemicrania. By regulation of the P2Y-like receptors one can also treat visceral pain as pancreatitis, intestinal cystitis, dysmenorrhea, irritable Bowel syndrome, Crohn's disease, biliary colic, urethral colic, myocardial infarction and pain syndromes of the pelvic cavity, e.g. vulvodynia, orchialgia, urethral syndrome and protatodynia. P2Y-like can also be used to treat  
25 acute pain for example postoperative pain and pain after trauma.

This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For  
30 example, an agent identified as described herein (e.g., a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a P2Y-like GPCR

polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

A reagent which affects P2Y-like GPCR activity can be administered to a human cell, either *in vitro* or *in vivo*, to reduce P2Y-like GPCR activity. The reagent preferably binds to an expression product of a human P2Y-like GPCR gene. If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5  $\mu\text{g}$  of DNA per 16 nmole of liposome delivered to about  $10^6$  cells, more preferably about 1.0  $\mu\text{g}$  of DNA per 16 nmole of liposome delivered to about  $10^6$  cells, and even more preferably about 2.0  $\mu\text{g}$  of DNA per 16 nmol of liposome delivered to about  $10^6$  cells. Preferably, a liposome is between about 100 and

500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

Suitable liposomes for use in the present invention include those liposomes  
5 standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell types, such as a cell-specific ligand exposed on the  
10 outer surface of the liposome.

Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 µg to about 10 µg of  
15 polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 µg to about 5 µg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 µg of polynucleotides is combined with about 8 nmol liposomes.

20 In another embodiment, antibodies can be delivered to specific tissues *in vivo* using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis *et al.* *Trends in Biotechnol.* 11, 202-05 (1993); Chiou *et al.*, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem.* 263, 621-24 (1988);  
25 Wu *et al.*, *J. Biol. Chem.* 269, 542-46 (1994); Zenke *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87, 3655-59 (1990); Wu *et al.*, *J. Biol. Chem.* 266, 338-42 (1991).

#### Determination of a Therapeutically Effective Dose

30 The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of

active ingredient which increases or decreases P2Y-like GPCR activity relative to the P2Y-like GPCR activity which occurs in the absence of the therapeutically effective dose.

5 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

10

Therapeutic efficacy and toxicity, *e.g.*, ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it  
15 can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>.

20

Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

25

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and  
30 tolerance/response to therapy. Long-acting pharmaceutical compositions can be

administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

5 Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations,  
10 etc.

If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated  
15 DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

20 Effective *in vivo* dosages of an antibody are in the range of about 5  $\mu$ g to about 50  $\mu$ g/kg, about 50  $\mu$ g to about 5 mg/kg, about 100  $\mu$ g to about 500  $\mu$ g/kg of patient body weight, and about 200 to about 250  $\mu$ g/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo* dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg,  
25 about 1  $\mu$ g to about 2 mg, about 5  $\mu$ g to about 500  $\mu$ g, and about 20  $\mu$ g to about 100  $\mu$ g of DNA.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides  
30 or ribozymes can be introduced into cells by a variety of methods, as described above.

Preferably, a reagent reduces expression of a P2Y-like GPCR gene or the activity of a P2Y-like GPCR polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a P2Y-like GPCR gene or the activity of a P2Y-like GPCR polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to P2Y-like GPCR-specific mRNA, quantitative RT-PCR, immunologic detection of a P2Y-like GPCR polypeptide, or measurement of P2Y-like GPCR activity.

In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

#### Diagnostic Methods

GPCRs also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences which encode a GPCR. Such diseases, by way of example, are related to cell transformation, such as tumors and cancers, and various cardiovascular disorders, including hypertension and hypotension, as well as diseases

arising from abnormal blood flow, abnormal angiotensin-induced aldosterone secretion, and other abnormal control of fluid and electrolyte homeostasis.

5 According to the present invention, differences can be determined between the cDNA or genomic sequence encoding a P2Y-like GPCR in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.

10 Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template  
15 molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.

Genetic testing based on DNA sequence differences can be carried out by detection  
20 of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions  
25 according to their specific melting or partial melting temperatures (*see, e.g., Myers et al., Science* 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (*e.g., Cotton et al., Proc. Natl. Acad. Sci. USA* 85, 4397-4401, 1985). Thus, the detection of a specific DNA sequence can be performed by  
30 methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA.



In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

Altered levels of a P2Y-like GPCR also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

#### EXAMPLE 1

##### *Detection of P2Y-like GPCR activity*

The polynucleotide of SEQ ID NO. 4 is inserted into the expression vector pCEV4 and the expression vector pCEV4-P2Y-like GPCR polypeptide obtained is transfected into human embryonic kidney 293 cells. The cells are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication. Cell lysates are centrifuged at 1000 rpm for 5 minutes at 4 °C. The supernatant is centrifuged at 30,000 x g for 20 minutes at 4 °C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO<sub>4</sub>, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 % BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10 % of an added radioligand, i.e. <sup>125</sup>I-labeled P2Y, are added to 96-well polypropylene microtiter plates containing ligand, non-labeled peptides, and binding buffer to a final volume of 250 µl.

In equilibrium saturation binding assays, membrane preparations are incubated in the presence of increasing concentrations (0.1 nM to 4 nM) of  $^{125}\text{I}$  ligand.

5 Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program. Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane  
10 protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. The P2Y-like GPCR activity of the polypeptide comprising the amino acid sequence of SEQ ID NO. 2 is demonstrated.

## 15 EXAMPLE 2

### *Radioligand binding assays*

Human embryonic kidney 293 cells transfected with a polynucleotide which  
20 expresses human P2Y-like GPCR are scraped from a culture flask into 5 ml of Tris HCl, 5 mM EDTA, pH 7.5, and lysed by sonication. Cell lysates are centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant is centrifuged at 30,000 x g for 20 minutes at 4°C. The pellet is suspended in binding buffer containing 50 mM Tris HCl, 5 mM MgSO<sub>4</sub>, 1 mM EDTA, 100 mM NaCl, pH 7.5, supplemented with 0.1 %  
25 BSA, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon. Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10 % of the added radioligand, i.e. P2Y, are added to 96-well polypropylene microtiter plates containing  $^{125}\text{I}$ -labeled ligand or test compound, non-labeled peptides, and binding buffer to a final volume of 250 µl.

- 70 -

In equilibrium saturation binding assays, membrane preparations are incubated in the presence of increasing concentrations (0.1 nM to 4 nM) of  $^{125}\text{I}$ -labeled ligand or test compound (specific activity 2200 Ci/mmol). The binding affinities of different test compounds are determined in equilibrium competition binding assays, using 0.1 nM  $^{125}\text{I}$ -peptide in the presence of twelve different concentrations of each test compound.

Binding reaction mixtures are incubated for one hour at 30°C. The reaction is stopped by filtration through GF/B filters treated with 0.5% polyethyleneimine, using a cell harvester. Radioactivity is measured by scintillation counting, and data are analyzed by a computerized non-linear regression program.

Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of unlabeled peptide. Protein concentration is measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard. A test compound which increases the radioactivity of membrane protein by at least 15% relative to radioactivity of membrane protein which was not incubated with a test compound is identified as a compound which binds to a human P2Y-like GPCR polypeptide.

### EXAMPLE 3

#### *Effect of a test compound on human P2Y-like GPCR-mediated cyclic AMP formation*

Receptor-mediated inhibition of cAMP formation can be assayed in host cells which express human P2Y-like GPCR. Cells are plated in 96-well plates and incubated in Dulbecco's phosphate buffered saline (PBS) supplemented with 10 mM HEPES, 5 mM theophylline, 2 µg/ml aprotinin, 0.5 mg/ml leupeptin, and 10 µg/ml phosphoramidon for 20 minutes at 37°C in 5% CO<sub>2</sub>. A test compound is added and incubated for an additional 10 minutes at 37°C. The medium is aspirated, and the reaction is stopped by the addition of 100 mM HCl. The plates are stored at 4°C for

- 71 -

15 minutes. cAMP content in the stopping solution is measured by radioimmunoassay.

5 Radioactivity is quantified using a gamma counter equipped with data reduction software. A test compound which decreases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound is identified as a potential inhibitor of cAMP formation. A test compound which increases radioactivity of the contents of a well relative to radioactivity of the contents of a well in the absence of the test compound is identified as a potential  
10 enhancer of cAMP formation.

#### EXAMPLE 4

##### *Effect of a test compound on the mobilization of intracellular calcium*

15 Intracellular free calcium concentration can be measured by microspectrofluorometry using the fluorescent indicator dye Fura-2/AM (Bush *et al.*, *J. Neurochem.* 57, 562-74, 1991). Stably transfected cells are seeded onto a 35 mm culture dish containing a glass coverslip insert. Cells are washed with HBS, incubated with a test compound,  
20 and loaded with 100  $\mu$ l of Fura-2/AM (10  $\mu$ M) for 20-40 minutes. After washing with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10-20 minutes. Cells are then visualized under the 40X objective of a Leitz Fluovert FS microscope.

25 Fluorescence emission is determined at 510 nm, with excitation wavelengths alternating between 340 nm and 380 nm. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques. A test compound which increases the fluorescence by at least 15% relative to fluorescence in the absence of a test compound is identified as a  
30 compound which mobilizes intracellular calcium.

### EXAMPLE 5

#### *Effect of a test compound on phosphoinositide metabolism*

5 Cells which stably express human P2Y-like GPCR cDNA are plated in 96-well plates and grown to confluence. The day before the assay, the growth medium is changed to 100  $\mu$ l of medium containing 1% serum and 0.5  $\mu$ Ci  $^3$ H-myo-inositol. The plates are incubated overnight in a CO<sub>2</sub> incubator (5% CO<sub>2</sub> at 37°C). Immediately before the assay, the medium is removed and replaced by 200  $\mu$ l of PBS containing 10 mM  
10 LiCl, and the cells are equilibrated with the new medium for 20 minutes. During this interval, cells also are equilibrated with antagonist, added as a 10  $\mu$ l aliquot of a 20-fold concentrated solution in PBS.

The  $^3$ H-inositol phosphate accumulation from inositol phospholipid metabolism is  
15 started by adding 10  $\mu$ l of a solution containing a test compound. To the first well 10  $\mu$ l are added to measure basal accumulation. Eleven different concentrations of test compound are assayed in the following 11 wells of each plate row. All assays are performed in duplicate by repeating the same additions in two consecutive plate rows.

20 The plates are incubated in a CO<sub>2</sub> incubator for one hour. The reaction is terminated by adding 15  $\mu$ l of 50% v/v trichloroacetic acid (TCA), followed by a 40 minute incubation at 4°C. After neutralizing TCA with 40  $\mu$ l of 1 M Tris, the content of the wells is transferred to a Multiscreen HV filter plate (Millipore) containing Dowex  
25 AG1-X8 (200-400 mesh, formate form). The filter plates are prepared by adding 200  $\mu$ l of Dowex AG1-X8 suspension (50% v/v, water:resin) to each well. The filter plates are placed on a vacuum manifold to wash or elute the resin bed. Each well is washed 2 times with 200  $\mu$ l of water, followed by 2 x 200  $\mu$ l of 5 mM sodium tetraborate/60 mM ammonium formate.

30

The  $^3\text{H}$ -IPs are eluted into empty 96-well plates with 200  $\mu\text{l}$  of 1.2 M ammonium formate/0.1 formic acid. The content of the wells is added to 3 ml of scintillation cocktail, and radioactivity is determined by liquid scintillation counting.

5     EXAMPLE 6

*Receptor Binding Methods*

Standard Binding Assays. Binding assays are carried out in a binding buffer  
10     containing 50 mM HEPES, pH 7.4, 0.5% BSA, and 5 mM  $\text{MgCl}_2$ . The standard  
assay for radioligand (e.g.,  $^{125}\text{I}$ - test compound) binding to membrane fragments  
comprising P2Y-like GPCR polypeptides is carried out as follows in 96 well  
microtiter plates (e.g., Dynatech Immulon II Removawell plates). Radioligand is  
diluted in binding buffer+ PMSF/Baci to the desired cpm per 50  $\mu\text{l}$ , then 50  $\mu\text{l}$   
15     aliquots are added to the wells. For non-specific binding samples, 5  $\mu\text{l}$  of 40  $\mu\text{M}$   
cold ligand also is added per well. Binding is initiated by adding 150  $\mu\text{l}$  per well of  
membrane diluted to the desired concentration (10-30  $\mu\text{g}$  membrane protein/well) in  
binding buffer+ PMSF/Baci. Plates are then covered with Linbro mylar plate sealers  
(Flow Labs) and placed on a Dynatech Microshaker II. Binding is allowed to  
20     proceed at room temperature for 1-2 hours and is stopped by centrifuging the plate  
for 15 minutes at 2,000 x g. The supernatants are decanted, and the membrane  
pellets are washed once by addition of 200  $\mu\text{l}$  of ice cold binding buffer, brief  
shaking, and recentrifugation. The individual wells are placed in 12 x 75 mm tubes  
and counted in an LKB Gammamaster counter (78% efficiency). Specific binding by  
25     this method is identical to that measured when free ligand is removed by rapid (3-5  
seconds) filtration and washing on polyethyleneimine-coated glass fiber filters.

Three variations of the standard binding assay are also used.

1. Competitive radioligand binding assays with a concentration range of cold ligand vs.  $^{125}$ I-labeled ligand are carried out as described above with one modification. All dilutions of ligands being assayed are made in 40X PMSF/Baci to a concentration 40X the final concentration in the assay. Samples of peptide (5  $\mu$ l each) are then added per microtiter well. Membranes and radioligand are diluted in binding buffer without protease inhibitors. Radioligand is added and mixed with cold ligand, and then binding is initiated by addition of membranes.
2. Chemical cross-linking of radioligand with receptor is done after a binding step identical to the standard assay. However, the wash step is done with binding buffer minus BSA to reduce the possibility of non-specific cross-linking of radioligand with BSA. The cross-linking step is carried out as described below.
3. Larger scale binding assays to obtain membrane pellets for studies on solubilization of receptor:ligand complex and for receptor purification are also carried out. These are identical to the standard assays except that (a) binding is carried out in polypropylene tubes in volumes from 1-250 ml, (b) concentration of membrane protein is always 0.5 mg/ml, and (c) for receptor purification, BSA concentration in the binding buffer is reduced to 0.25%, and the wash step is done with binding buffer without BSA, which reduces BSA contamination of the purified receptor.

### EXAMPLE 7

#### *Chemical Cross-Linking of Radioligand to Receptor*

5 After a radioligand binding step as described above, membrane pellets are resuspended in 200  $\mu$ l per microtiter plate well of ice-cold binding buffer without BSA. Then 5  $\mu$ l per well of 4 mM N-5-azido-2-nitrobenzoyloxysuccinimide (ANB-NOS, Pierce) in DMSO is added and mixed. The samples are held on ice and UV-irradiated for 10 minutes with a Mineralight R-52G lamp (UVP Inc., San Gabriel,  
10 Calif.) at a distance of 5-10 cm. Then the samples are transferred to Eppendorf microfuge tubes, the membranes pelleted by centrifugation, supernatants removed, and membranes solubilized in Laemmli SDS sample buffer for polyacrylamide gel electrophoresis (PAGE). PAGE is carried out as described below. Radiolabeled proteins are visualized by autoradiography of the dried gels with Kodak XAR film  
15 and Dupont image intensifier screens.

### EXAMPLE 8

#### *Membrane Solubilization*

20 Membrane solubilization is carried out in buffer containing 25 mM Tris , pH 8, 10% glycerol (w/v) and 0.2 mM  $\text{CaCl}_2$  (solubilization buffer). The highly soluble detergents including Triton X-100, deoxycholate, deoxycholate:lysolecithin, CHAPS, and zwittergent are made up in solubilization buffer at 10% concentrations and stored as frozen aliquots. Lysolecithin is made up fresh because of insolubility upon freeze-  
25 thawing and digitonin is made fresh at lower concentrations due to its more limited solubility.

To solubilize membranes, washed pellets after the binding step are resuspended free of visible particles by pipetting and vortexing in solubilization buffer at 100,000 x g  
30 for 30 minutes. The supernatants are removed and held on ice and the pellets are discarded.



EXAMPLE 9*Assay of Solubilized Receptors*

After binding of  $^{125}\text{I}$  ligands and solubilization of the membranes with detergent, the intact R:L complex can be assayed by four different methods. All are carried out on ice or in a cold room at 4-10°C):

1. Column chromatography (Knuhtsen *et al.*, *Biochem. J.* 254, 641-647, 1988). Sephadex G-50 columns (8 x 250 mm) are equilibrated with solubilization buffer containing detergent at the concentration used to solubilize membranes and 1 mg/ml bovine serum albumin. Samples of solubilized membranes (0.2-0.5 ml) are applied to the columns and eluted at a flow rate of about 0.7 ml/minute. Samples (0.18 ml) are collected. Radioactivity is determined in a gamma counter. Void volumes of the columns are determined by the elution volume of blue dextran. Radioactivity eluting in the void volume is considered bound to protein. Radioactivity eluting later, at the same volume as free  $^{125}\text{I}$  ligands, is considered non-bound.
2. Polyethyleneglycol precipitation (Cuatrecasas, *Proc. Natl. Acad. Sci. USA* 69, 318-322, 1972). For a 100  $\mu\text{l}$  sample of solubilized membranes in a 12 x 75 mm polypropylene tube, 0.5 ml of 1% (w/v) bovine gamma globulin (Sigma) in 0.1 M sodium phosphate buffer is added, followed by 0.5 ml of 25% (w/v) polyethyleneglycol (Sigma) and mixing. The mixture is held on ice for 15 minutes. Then 3 ml of 0.1 M sodium phosphate, pH 7.4, is added per sample. The samples are rapidly (1-3 seconds) filtered over Whatman GF/B glass fiber filters and washed with 4 ml of the phosphate buffer. PEG-precipitated receptor :  $^{125}\text{I}$ -ligand complex is determined by gamma counting of the filters.

- 77 -

3. GFB/PEI filter binding (Bruns *et al.*, *Analytical Biochem.* 132, 74-81, 1983). Whatman GF/B glass fiber filters are soaked in 0.3% polyethyleneimine (PEI, Sigma) for 3 hours. Samples of solubilized membranes (25-100  $\mu$ l) are replaced in 12 x 75 mm polypropylene tubes. Then 4 ml of solubilization buffer without detergent is added per sample and the samples are immediately filtered through the GFB/PEI filters (1-3 seconds) and washed with 4 ml of solubilization buffer. CPM of receptor :  $^{125}$ I-ligand complex adsorbed to filters are determined by gamma counting.
4. Charcoal/Dextran (Paul and Said, *Peptides 7[Suppl. 1]*, 147-149, 1986). Dextran T70 (0.5 g, Pharmacia) is dissolved in 1 liter of water, then 5 g of activated charcoal (Norit A, alkaline; Fisher Scientific) is added. The suspension is stirred for 10 minutes at room temperature and then stored at 4°C. until use. To measure R:L complex, 4 parts by volume of charcoal/dextran suspension are added to 1 part by volume of solubilized membrane. The samples are mixed and held on ice for 2 minutes and then centrifuged for 2 minutes at 11,000 x g in a Beckman microfuge. Free radioligand is adsorbed charcoal/dextran and is discarded with the pellet. Receptor :  $^{125}$ I-ligand complexes remain in the supernatant and are determined by gamma counting.

### EXAMPLE 10

#### *Receptor Purification*

Binding of biotinyl-receptor to GH<sub>4</sub> C1 membranes is carried out as described above. Incubations are for 1 hour at room temperature. In the standard purification protocol, the binding incubations contain 10 nM Bio-S29.  $^{125}$ I ligand is added as a tracer at levels of 5,000-100,000 cpm per mg of membrane protein. Control incubations contain 10  $\mu$ M cold ligand to saturate the receptor with non-biotinylated ligand.

Solubilization of receptor:ligand complex also is carried out as described above, with 0.15% deoxycholate:lysolecithin in solubilization buffer containing 0.2 mM  $\text{MgCl}_2$ , to obtain 100,000 x g supernatants containing solubilized R:L complex.

- 5     Immobilized streptavidin (streptavidin cross-linked to 6% beaded agarose, Pierce Chemical Co.; "SA-agarose") is washed in solubilization buffer and added to the solubilized membranes as 1/30 of the final volume. This mixture is incubated with constant stirring by end-over-end rotation for 4-5 hours at 4-10°C. Then the mixture is applied to a column and the non-bound material is washed through. Binding of  
10     radioligand to SA-agarose is determined by comparing cpm in the 100,000 x g supernatant with that in the column effluent after adsorption to SA-agarose. Finally, the column is washed with 12-15 column volumes of solubilization buffer+0.15% deoxycholate:lysolecithin +1/500 (vol/vol) 100 x 4pase.
- 15     The streptavidin column is eluted with solubilization buffer+0.1 mM EDTA+0.1 mM EGTA+0.1 mM GTP- $\gamma$ -S (Sigma)+0.15% (wt/vol) deoxycholate:lysolecithin +1/1000 (vol/vol) 100.times.4pase. First, one column volume of elution buffer is passed through the column and flow is stopped for 20-30 minutes. Then 3-4 more column volumes of elution buffer are passed through. All the eluates are pooled.
- 20     Eluates from the streptavidin column are incubated overnight (12-15 hours) with immobilized wheat germ agglutinin (WGA agarose, Vector Labs) to adsorb the receptor via interaction of covalently bound carbohydrate with the WGA lectin. The ratio (vol/vol) of WGA-agarose to streptavidin column eluate is generally 1:400. A  
25     range from 1:1000 to 1:200 also can be used. After the binding step, the resin is pelleted by centrifugation, the supernatant is removed and saved, and the resin is washed 3 times (about 2 minutes each) in buffer containing 50 mM HEPES, pH 8, 5 mM  $\text{MgCl}_2$  and 0.15% deoxycholate:lysolecithin. To elute the WGA-bound  
30     receptor, the resin is extracted three times by repeated mixing (vortex mixer on low speed) over a 15-30 minute period on ice, with 3 resin columns each time, of 10 mM N-N'-N''-triacetylchitotriose in the same HEPES buffer used to wash the resin. After

each elution step, the resin is centrifuged down and the supernatant is carefully removed, free of WGA-agarose pellets. The three, pooled eluates contain the final, purified receptor. The material non-bound to WGA contain G protein subunits specifically eluted from the streptavidin column, as well as non-specific contaminants. All these fractions are stored frozen at -90°C.

#### EXAMPLE 11

##### *Identification of test compounds that bind to P2Y-like GPCR polypeptides*

Purified P2Y-like GPCR polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. P2Y-like GPCR polypeptides comprise an amino acid sequence shown in SEQ ID NO. 2. The test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a P2Y-like GPCR polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound was not incubated is identified as a compound which binds to a P2Y-like GPCR polypeptide.

#### EXAMPLE 12

##### *Identification of a test compound which decreases P2Y-like GPCR gene expression*

A test compound is administered to a culture of human gastric cells and incubated at 37°C for 10 to 45 minutes. A culture of the same type of cells incubated for the same time without the test compound provides a negative control.

RNA is isolated from the two cultures as described in Chirgwin *et al.*, *Biochem.* 18, 5294-99, 1979). Northern blots are prepared using 20 to 30 µg total RNA and hybridized with a <sup>32</sup>P-labeled P2Y-like GPCR-specific probe at 65°C in Express-hyb (CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 4 or 5. A test compound which decreases the P2Y-like GPCR-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of P2Y-like GPCR gene expression.

### 10 EXAMPLE 13

*Treatment of a disease in which human P2Y-like GPCR is overexpressed with a reagent which specifically binds to a P2Y-like GPCR gene product*

15 Synthesis of antisense P2Y-like GPCR oligonucleotides comprising at least 11 contiguous nucleotides selected from the complement of SEQ ID NO. 4 or 5 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann *et al.*, *Chem. Rev.* 90, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate-buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation are determined using the Luminous Amebocyte Assay (Bang, *Biol. Bull. (Woods Hole, Mass.)* 105, 361-362, 1953).

25 The antisense oligonucleotides are administered to a patient. The severity of the patient's disease is decreased.

#### EXAMPLE 14

##### *Tissue-specific expression of P2Y-like GPCR*

5 As a first step to establishing a role for P2Y-like GPCR in disease states, expression profiling of the gene was done using real-time quantitative PCR (TaqMan) with RNA samples isolated from a wide range of human tissues and cells. Total RNA samples were either purchased from commercial suppliers or purified in-house. Three panels of RNAs were used for profiling: an organ panel (Table 1), a CNS specific panel  
10 (Table 2), and a respiratory specific panel (Table 3).

*Real-time quantitative PCR.* This technique is a development of the kinetic analysis of PCR first described by Higuchi *et al.* (*BioTechnology* 10, 413-17, 1992; *BioTechnology* 11, 1026-30, 1993). The principle is that at any given cycle within the  
15 exponential phase of PCR, the amount of product is proportional to the initial number of template copies. PCR amplification is performed in the presence of an oligonucleotide probe (TaqMan probe) that is complementary to the target sequence and labeled with a fluorescent reporter dye and a quencher dye. During the extension phase of PCR the probe is cleaved by the 5'-3' endonuclease activity of Taq DNA  
20 polymerase, releasing the fluorophore from the effect of the quenching dye (Holland *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88, 7276-80, 1991). Because the fluorescence emission increases in direct proportion to the amount of the specific amplified product, the exponential growth phase of PCR product can be detected and used to determine the initial template concentration (Heid *et al.*, *Genome Res.* 6, 986-94,  
25 1996, and Gibson *et al.*, *Genome Res.* 6, 995-1001, 1996). In addition, simultaneous amplification of an endogenous control can be performed to standardize the amount of sample RNA used in the reaction. In such experiments the control of choice is 18S ribosomal RNA. Reporter dyes with differing emission spectra are available, which enables the target and the endogenous control to be independently quantified  
30 in the same tube.

*RNA purification.* Total RNAs from the in-house samples detailed in Tables 1 and 2 were isolated using TRIzol (Life Technologies) extraction according to the manufacturer's protocols. The concentration of purified RNA was determined spectrophotometrically by measurement of absorbance at 260nm. RNAs from the in-house samples listed in Table 3 were purified using Qiagen's (Crawley, West Sussex, UK) RNeasy system according to the manufacturer's protocol. Ribogreen RNA quantitation kit (Molecular Probes Europe, The Netherlands) was used to determine the concentration of purified RNA in the samples.

*cDNA preparation.* For samples listed in Tables 1 and 2, 50 µg of each RNA were treated with DNase I for 1 hour at 37°C in the following reaction mix:

	DNase I, RNase-free (Roche Diagnostics, Germany)	0.2 U/µL
	RNase inhibitor (PE Applied Biosystems, CA)	0.4 U/µL
15	Tris-HCl pH 7.9	10mM
	MgCl <sub>2</sub>	10mM
	NaCl	50mM
	DTT	1mM

RNA was then extracted once with 1 volume of phenol:chloroform:isoamyl alcohol (24:24:1) and once with chloroform, and then precipitated with 1/10 volume of 3M NaAcetate, pH5.2, and finally with 2 volumes of absolute ethanol.

After spectrophotometric quantification, each sample was reverse transcribed with TaqMan Reverse Transcription Reagents (PE Applied Biosystems, CA) according to the manufacturer's protocol. The concentration of RNA in the reaction was 200 ng/µL and reverse transcription was done with random hexamer primers at a concentration of 2.5µM.

For samples listed in Table 3, 1 µg of total RNA was reverse transcribed in a final volume of 20 µl, using 200U of SUPERSCRIPT™II RNase H<sup>-</sup> Reverse Transcriptase (Life Technologies, Paisley, UK), 10 mM dithiothreitol, 0.5 mM of each

dNTP and 5  $\mu$ M random hexamers (Applied Biosystems, Warrington, Cheshire, UK) according to the manufacturer's protocol.

*Expression analysis I: Human organ and CNS specific tissues.*

5

Specific primers and probe were designed according to the recommendations of PE Applied Biosystems and are listed below:

forward primer: 5'-AGCTGCTGCCCACACTGG-3'  
 10 reverse primer: 5'-CTCTTGGCTGGTCATGTCATACC-3'  
 probe: 5'-(FAM) CCCACACGGACTACATCAATGGCCAG (TAMRA)-3'

where FAM = 6-carboxy-fluorescein and TAMRA = 6-carboxy-tetramethyl-rhodamine.

15

Quantitative PCR was performed with 10ng of reverse transcribed RNA from each sample. Each determination was done in triplicate.

Total cDNA content was normalized by simultaneous quantification (multiplex PCR)  
 20 of the 18S ribosomal RNA by using a Pre-Developed TaqMan Assay Reagents (PDAR) Control Kit (PE Applied Biosystems, CA). The assay reaction mix was as follows:

	<u>Final conc.</u>
TaqMan Universal PCR Master Mix (2x)	1x
25 (PE Applied Biosystems, CA)	
PDAR control -- 18S RNA (20x)	1x
Forward primer	300nM
Reverse primer	900nM
Probe	200nM
30 cDNA	10ng
Water	to 25 $\mu$ L



For PCR, the following steps were carried out once: pre PCR, 2 minutes at 50°C, and 10 minutes at 95°C. The following steps were carried out 40 times: denaturation, 15s at 95°C; annealing/extension, 60s at 60°C. All experiments were performed on an  
5 ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA). At the end of the run, fluorescence data acquired during PCR were processed as described in the ABI Prism 7700 user's manual in order to achieve better background subtraction as well as signal linearity with the starting target quantity.

10 The expression of P2Y-like GPCR in various human tissues is shown in Figure 7. By far the highest level of expression was in fetal brain but there was clear expression in many tissues. Of particular interest was detection of expression of P2Y-like GPCR in brain and lung (for further analysis see below) tissues. Detailed  
15 investigation of the expression of the receptor in various regions of adult brain and spinal cord revealed ubiquitous expression across the CNS, with cerebellum exhibiting the highest level of expression (Figure 8). The ubiquitous expression in the nervous system supports the regulation of human P2Y-like receptors to treat disorders of the nervous system. The particularly high expression in the cerebellum could reflect the importance of P2Y-like receptors in diseases of the motor unit like  
20 neurogenic and myopathic disorders.

*Expression analysis II:* Human respiratory tissues and cells. Specific primers and probe were designed according to the recommendations of PE Applied Biosystems and are listed below:

25

forward primer: 5'-CTGCCCACACTGGCCTTCT-3'

reverse primer: 5'-TGTCAGAACTATGCCGTAGGCA-3'

probe: 5'-(FAM)-CACACGGACTACATCAATGGCCAGATGATCT-3'

30

where FAM = 6-carboxy-fluorescein.

Quantitative PCR was performed with 10ng of reverse transcribed RNA from each sample. Each determination was done in duplicate.

The assay reaction mix was as follows:

5		<u>Final conc.</u>
	TaqMan Universal PCR Master Mix (2x stock)	1x
	(PE Applied Biosystems, Warrington, UK)	
	Forward primer	900nM
	Reverse primer	900nM
10	Probe	200nM
	cDNA	10ng
	Water	to 25 $\mu$ L

The following steps were carried out once: pre PCR, 2 minutes at 50°C, and  
 15 10 minutes at 95°C. The following steps were carried out 40 times: denaturation, 15 seconds at 95°C; annealing/extension, 1 minute at 60°C.

As above, all experiments were performed using an ABI Prism 7700 Sequence  
 20 Detector (Applied Biosystems, CA). The C<sub>T</sub> value generated for each reaction was used to determine the initial template concentration (copy number) by interpolation from a universal standard curve. The level of expression of the P2Y-like GPCR gene in each sample was calculated relative to the sample with the lowest expression of the gene.

25 Fig. 9 shows the expression of P2Y-like GPCR in a range of respiratory tissues and cells. In these samples, the highest level of expression was detected in whole lung. Investigation of expression of the receptor in some of the constituent cell types of the lung demonstrated significant expression in alveolar type II cells. Expression of the gene in lung inflammatory cell types (PMN, monocyte, macrophage) was generally  
 30 very low except for one of the PMN samples.

The relatively high level of expression of P2Y-like GPCR in alveolar type II cells is of particular interest. *In vitro* studies have shown that activation of P2 purinoceptors, especially the P2Y<sub>2</sub> receptor, stimulates surfactant secretion from type II cells (Warburton et al. J. Appl. Physiol. 66, 901-905, 1989; Gricse et al., Biochim. Biophys. Acta 1167, 85-93, 1993; Gobran et al., Am. J. Physiol. 16, L187-L196, 1997), raising the possibility that such receptors may have a physiological role in the regulation of surfactant secretion. Since small airway closure in obstructive diseases such as COPD most likely results from insufficient secretion of surfactant, one possible therapeutic approach to this disease is to stimulate secretion via activation of P2Y GPCRs. The novel P2Y-like GPCR reported here, and demonstration of its expression in alveolar type II cells, represents a potential target for the treatment of COPD.

**Table 1** Human organ RNA panel used for real-time quantitative PCR

Tissue	Supplier, cat. #
Adrenal gland	Clontech (CA, USA), 640161
Bladder	Invitrogen (CA, USA), D602001
Brain (fetal)	Clontech, 640191
Brain	OriGene (MD, USA), HT1001
Colon	OriGene, HT1015
Gastric mucosa	In-house
Heart	OriGene, HT1002
Liver (fetal)	Clontech, 640181
Liver	OriGene, HT1005
Lung	OriGene, HT1009
Kidney	OriGene, HT1003
Muscle	OriGene, HT1008
Pancreas	Clontech, 640311
Placenta	OriGene, HT1013

- 87 -

Tissue	Supplier, cat. #
Prostate	Clontech, 640381
Prostate	In-house
Spleen	OriGene, HT1004
Testis	OriGene, HT1011
Thymus	Clontech, 640281
Trachea	Clontech, 640911

**Table 2** CNS specific RNA panel used for real-time quantitative PCR.

Tissue	Supplier, cat #
Brain	In-house
Cortex	In-house
Choroid plexus	In-house
Hippocampus	In-house
Hypothalamus	In-house
Amygdala	In-house
Thalamus	In-house
Cerebellum	In-house
Cerebellum	Clontech, 640351
Spinal Cord	Clontech, K40031

**Table 3** Human respiratory specific RNA panel used for real-time quantitative PCR.

Tissue/cell type	Supplier, cat #
Lung (fetal)	Takara (Japan)
Lung	Clontech, 64023-1
Trachea	Clontech, K4000-1
Cultured human bronchial epithelial cells	In-house
Cultured airway smooth muscle cells	In-house
Cultured small airway epithelial cells	In-house
Primary cultured alveolar type II cells	In-house
Cultured H441 cells (Clara-like)	In-house
Freshly isolated polymorphonuclear leukocytes (neutrophils)	In-house
Freshly isolated monocytes	In-house
Cultured monocytes (macrophage-like)	In-house

CLAIMS

1. An isolated polynucleotide encoding a P2Y-like GPCR polypeptide and being selected from the group consisting of:
- 5
- a) a polynucleotide encoding a P2Y-like GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:
- 10 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2; and the amino acid sequence shown in SEQ ID NO. 2.
- b) a polynucleotide comprising the sequence of SEQ ID NOS. 4 or 5;
- 15 c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
- 20 e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d).
- 25 2. An expression vector containing any polynucleotide of claim 1.
3. A host cell containing the expression vector of claim 2.
4. A substantially purified P2Y-like GPCR polypeptide encoded by a polynucleotide of claim 1.
- 30

5. A method for producing a P2Y-like GPCR polypeptide, wherein the method comprises the following steps:
- 5 a) culturing the host cell of claim 3 under conditions suitable for the expression of the P2Y-like GPCR polypeptide; and
- b) recovering the P2Y-like GPCR polypeptide from the host cell culture.
- 10 6. A method for detection of a polynucleotide encoding a P2Y-like GPCR polypeptide in a biological sample comprising the following steps:
- a) hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- 15 b) detecting said hybridization complex.
7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
- 20 8. A method for the detection of a polynucleotide of claim 1 or a P2Y-like GPCR polypeptide of claim 4 comprising the steps of:
- contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the P2Y-like GPCR polypeptide and detecting the interaction.
- 25
9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
10. A method of screening for agents which decrease the activity of a P2Y-like GPCR, comprising the steps of:
- 30

contacting a test compound with any P2Y-like GPCR polypeptide encoded by any polynucleotide of claim 1;

5 detecting binding of the test compound to the P2Y-like GPCR polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a P2Y-like GPCR.

11. A method of screening for agents which regulate the activity of a P2Y-like GPCR, comprising the steps of:

10 contacting a test compound with a P2Y-like GPCR polypeptide encoded by any polynucleotide of claim 1; and

15 detecting a P2Y-like GPCR activity of the polypeptide, wherein a test compound which increases the P2Y-like GPCR activity is identified as a potential therapeutic agent for increasing the activity of the P2Y-like GPCR, and wherein a test compound which decreases the P2Y-like GPCR activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the P2Y-like GPCR.

12. A method of screening for agents which decrease the activity of a P2Y-like GPCR, comprising the steps of:

25 contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of P2Y-like GPCR.

13. A method of reducing the activity of P2Y-like GPCR, comprising the steps of:

30



contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any P2Y-like GPCR polypeptide of claim 4, whereby the activity of P2Y-like GPCR is reduced.

- 5      14. A reagent that modulates the activity of a P2Y-like GPCR polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claims 10 to 12.
- 10      15. A pharmaceutical composition, comprising:  
the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.
- 15      16. Use of the pharmaceutical composition of claim 15 for modulating the activity of a P2Y-like GPCR in a disease.
- 20      17. Use of claim 16 wherein the disease is COPD, peripheral or central nervous system disease, benign prostatic hyperplasia or urinary incontinence.
- 25      18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
19. The cDNA of claim 18 which comprises SEQ ID NO. 4.
- 20      20. The cDNA of claim 18 which consists of SEQ ID NO. 4.
21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
- 30      22. The expression vector of claim 21 wherein the polynucleotide consists of SEQ ID NO. 4.

23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
- 5 24. The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO. 4.
25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2.
- 10 26. The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO. 2.
- 15 27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO. 2.
28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:
- 20 culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and isolating the polypeptide.
- 25 29. The method of claim 28 wherein the expression vector comprises SEQ ID NO. 4.
30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:

hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 4 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and detecting the hybridization complex.

5      31.    The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.

32.    A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising:

10

a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO. 4; and instructions for the method of claim 30.

15      33.    A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising the steps of:

contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and detecting the reagent-polypeptide complex.

20

34.    The method of claim 33 wherein the reagent is an antibody.

35.    A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2, comprising:

25

an antibody which specifically binds to the polypeptide; and instructions for the method of claim 33.

30      36.    A method of screening for agents which can regulate the activity of a P2Y-like GPCR protein, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2; and  
5 detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the P2Y-like GPCR protein.

10 37. The method of claim 36 wherein the step of contacting is in a cell.

38. The method of claim 36 wherein the cell is *in vitro*.

39. The method of claim 36 wherein the step of contacting is in a cell-free system.

15 40. The method of claim 36 wherein the polypeptide comprises a detectable label.

41. The method of claim 36 wherein the test compound comprises a detectable label.

20 42. The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.

43. The method of claim 36 wherein the polypeptide is bound to a solid support.

25 44. The method of claim 36 wherein the test compound is bound to a solid support.

30 45. A method of screening for agents which regulate an activity of a human human P2Y-like GPCR protein, comprising the steps of:

contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO. 2 and (2) the amino acid sequence shown in SEQ ID NO. 2; and

5

detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human P2Y-like GPCR protein, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human P2Y-like GPCR protein.

10

46. The method of claim 45 wherein the step of contacting is in a cell.

15

47. The method of claim 45 wherein the cell is *in vitro*.

48. The method of claim 45 wherein the step of contacting is in a cell-free system.

20

49. The method of claim 45 wherein the activity is cyclic AMP formation.

50. The method of claim 45 wherein the activity is mobilization of intracellular calcium.

25

51. The method of claim 45 wherein the activity is phosphoinositide metabolism.

52. A method of screening for agents which regulate an activity of a human P2Y-like GPCR protein, comprising the steps of:

30

contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO. 4; and

detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human P2Y-like GPCR protein.

5

53. The method of claim 52 wherein the product is a polypeptide.

54. The method of claim 52 wherein the product is RNA.

10

55. A method of reducing activity of a human P2Y-like GPCR protein, comprising the step of:

contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 4, whereby the activity of a human P2Y-like GPCR protein is reduced.

15

56. The method of claim 55 wherein the product is a polypeptide.

57. The method of claim 56 wherein the reagent is an antibody.

20

58. The method of claim 55 wherein the product is RNA.

59. The method of claim 58 wherein the reagent is an antisense oligonucleotide.

25

60. The method of claim 58 wherein the reagent is a ribozyme.

61. The method of claim 55 wherein the cell is *in vitro*.

62. The method of claim 55 wherein the cell is *in vivo*.

30

63. A pharmaceutical composition, comprising:

a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2; and

5 a pharmaceutically acceptable carrier.

64. The pharmaceutical composition of claim 63 wherein the reagent is an antibody.

10 65. A pharmaceutical composition, comprising:

a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO. 4; and

15 a pharmaceutically acceptable carrier.

66. The pharmaceutical composition of claim 65 wherein the reagent is a ribozyme.

20 67. The pharmaceutical composition of claim 65 wherein the reagent is an antisense oligonucleotide.

68. The pharmaceutical composition of claim 65 wherein the reagent is an antibody.

25 69. A pharmaceutical composition, comprising:

an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 2; and

30 a pharmaceutically acceptable carrier.

70. The pharmaceutical composition of claim 69 wherein the expression vector comprises SEQ ID NO. 4.
- 5 71. The method of claim 55 wherein the reagent is identified by the method of claim 36.
72. The method of claim 55 wherein the reagent is identified by the method of claim 45.
- 10 73. The method of claim 55 wherein the reagent is identified by the method of claim 52.
74. A method of treating a P2Y-like GPCR disorder, comprising the step of:
- 15 administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human P2Y-like GPCR protein, whereby symptoms of the P2Y-like GPCR disorder are ameliorated.
- 20 75. The method of claim 74 wherein the reagent is identified by the method of claim 36.
76. The method of claim 74 wherein the reagent is identified by the method of claim 45.
- 25 77. The method of claim 74 wherein the reagent is identified by the method of claim 52.



78. The method of claim 74 wherein the P2Y-like GPCR disorder is COPD, peripheral or central nervous system disease, benign prostatic hyperplasia or urinary incontinence.

Fig. 1

AAGGGTCACTTGCTACTCTACTATGGCCTATGTGGTTAGGACCAAATTGTGG  
GCAGTTTCGGCCCCCTGGGAATATACCTGCTTTTCTGGCTAGAATACCTCCCC  
TTGGAGATTTTCTGACTCTATGCAATGGATTCTAGCAGGAGGAGACACAGAG  
CTGGAGGTTCTGAGTACCCTGTTTAAATGACAGTGTCTATCCCACCACCATTT  
CTATCACAACCCAGCCTAGAGTAGACAGCATACAAGTCCATGTAAGGCCAAC  
CCTTTGGACCTGGTAAGTCTAGACGCCCAGCTTTGGAAGATTATTTGGCCCT  
TGTTGAATACTCTATTTTCTGGGGTTGGTCTCTTTTAAACAAGGCCTCTGA  
CTAGACTTTGGGGGACAAAGTTGAATGCCGGGTGGGGCAGAGGCTGATGCC  
ATGCTGAGGTCATGATGTTATGCTGTCCATTTTGCTTCCTTCCAGGGGAAGC  
AGAAGCGGGAGCCGTCGTGGAGCTCTGCTCCTGGAGGGAGCCTCCCAGGACA  
TGGAGAAGGTGGACATGAATACATCACAGGAACAAGGTCTTGCCAGTTCTC  
AGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATCATCTTTATC  
CTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAAACCA  
AGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCCGACCT  
GCTTTATGTGCTATTGCCCTTCTCATCATCACCTACTCACTAGATGACAGG  
TGGCCCTTCGGGGAGCTGCTCTGCAAGCTGGTGCACCTTCTGTTCTATATCA  
ACCTTTACGGCAGCATCCTGCTGCTGACCTGCATCTCTGTGCACCAGTTCTT  
AGGTGTGTGCCACCCACTGTGTTGCTGCCCTACCGGACCCGCAGGCATGCC  
TGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCTTCCAGCTGCTGCCCA  
CACTGGCCTTCTCCACACGGACTACATCAATGGCCAGATGATCTGGTATGA  
CATGACCAGCCAAGAGAATTTTGATCGGCTTTTGGCTACGGCATAGTTCTG  
ACATTGTCTGGCTTTCTTTCCCTCCTTGGTCAATTTGGTGTGCTATTCACTG  
ATGGTCAGGAGCCTGATCAAGCCAGAGGAGAACCTCATGAGGACAGGCAACA  
CAGCCCGAGCCAGGTCCATCCGGACCATCCTACTGGTGTGTGGCCTCTTCAC  
CCTCTGTTTTGTGCCCTTCCATATCACTCGCTCCTTCTACCTCACCATCTGC  
TTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGCAGCCAGTGTGGCCTACA  
AGATATGGAGGCCTCTGGTGAGTGTGAGCAGCTGCCTCAACCCAGTCTGTGA  
CTTTCTTTCAAGGGGGGCAAAAATAGAGTCAGGCTCCTCCAGAACTGAGGC  
AGAACAAGTTGGGTGAGCATCCAGCTGGGAGGAAGAGATGCCCAGGGTTGAA  
CAGATCTGGGTAAATGCCAAGGTGAAGCTTGGGAAAAACGAGCTCCAACACCA  
CTAGCAACAACCTTGTTTGTACACAGATGAGTGTGCTGGTGGGAGAGGGGCTCAA  
GACCTCCTAAAAGTGTCTGCTGCAAAGGACACTTTTATATTGATGTTAAGT  
GAGTTTAAAATAAGAGTATGGAGAGAGCCACTAAAACAAAGGAAAACCTTCT  
TAAAGAGAGCTGACATTGGTCTCTTGTCAATTCAGGTCTCAGCTCAAATGTCA  
CCTTCTCAGAGACCACTCTGCCCCACCCTAGCTAATGTTGACCTCTCTCCTC  
ATAACCCAATCACTGTATTCCCTTATATATTGTCTTTGCAACATTTATTACT  
ATCTGGACTTGGTGATTCATTTACTTATTTATGATCTCTTTCCACTGAATTA  
TATGCTCCAATAGGACAGAGATCTCCTCTGATGGCTGACCCCTCAATACCAG  
CCTCCATAGCAGGGCCTGGCACATAGTAAGGGCACAAACAGATAGGGGCTGAA  
TGAATGAGTGAGCAAATGGACCTGTAAATGAAACCTTACTATGAAAGAGCA  
CCTTTGCATGGAGGAACTCATTTAACCTCACATAATCCCTTGTGGTGGAG  
GCCATTGTTTCTCCATTTACAGAGAAGGAAAACCTGACACGCACAGCTCAAAG  
TAACTTGTTCAGGCTTACCCAGTGGGAGAATGCCCAGATCATAGGGTTGAAT  
GGAGCTTTCAAAGCCAGGCAGTGGCCTCTGAAGCACATGCTCCTAAGCGTGA  
AAGCTATGCCCCCATCCAAACACCAGCCTAGAGCTGGCCCAAGTTCTCCTTG

- 2/7 -

ACAATATCGGCTTGTCAATTTTAGGCCGGCTCGCTTGTTGACACAGTTGCTGT  
TATCTGCAGAACTGAGGAGACCTTGTGTGGTCTTTTACTACATTTCTTAA  
CCAGTGTTTTTGTAGTAAAAGCTATGCAGGATAAAATGGGAGATACAGAGT  
AAAGTGGCTTCAAGAAAACCTGATTCGCTTCATTTTATTTAAATTTAAACAT  
GATGTTGGAGATTATGAAAAAACTTCATCAATGTCTTAAGTCATAATGAT  
GTTTATTCCCTAAAAAGACTTTTTTTAGTTAAGATGCAAGGTAATCCAAAA  
GATAACCTTAAAAAAACCTCTCATTTATAACAATAATGATTTCCAAGGATT  
TCTCAGGTCTATACATAACATTATCTAGGCTGGGCACAGTGGCTCATGCCTG  
TAATCCCAGCACTTTGGGAGGCCAAGGCGGGCGGATCACCTGAGGTCAGGAG  
TTGAGACCAATCTGGCCAACATGGTGAACCCCATCTCTACTAAAAATACA  
AAAATTAGCTGGGCGTGGTGGCGGGTGCCTATAATCCCAGCTACTCGGGAGG  
CTGAGAAAGGAGAATCGCTTGAACCCGGGAGGCGGAGGTTGCAGTGAGCTGA  
AACTACGCCACTGCACTCCAGCCTGGGCAACAAGAGCGAACTCTTAAAAAA  
AAAATTATCTAATAATCTACTAATCTCCCTATGAAGAGAAGGTGGTTAAATT  
CTTTTTATAAGAAACAAGCATAACCCCTCATTACTATCTCACTCCAATTATG  
GGAAATGTCTGAGTAAACCATGT

Fig. 2

MEKVDMNTSQEQGLCQFSEKYKQVYLSLAYSIHFLGLPLNGTVLW  
HSWGQTKRWSCATTYLVNLMVADLLYVLLPFLITYSLDDRWPFGF  
LLCKLVHFLFYINLYGSILLTCSIVHQFLGVCHPLCSLPYRTRRHA  
WLGTTSTWALVVLQLLPTLAFSHTDYINGQMIWYDMTSQENFDRL  
FAYGIVLTLSGFSLLGHFVLFTDGQEPDQARGEPHEDRQHSPSQV  
HPDHPTGVWPLHPLFCALPYHSLLLPHHLLSAFSGLPALDGSQCGLQD  
MEASVKAMQDKMGDTE

Fig. 3

MSMANFTGGRNSCTFHFEFKQVLLPLVYSVVFLGLPLNAVVICQIWLARKA  
LTRTTIYMLNLAMADLLYVCSLPLLIYNYTQKDYWPFGDFTCKFVRFQFYTN  
LHGSILFLTCSVQRYMGICHPLASWHKKKGKLTWLVCAAVWFIVIAQCLP  
TFVFASTGTQRNRTVCYDLSPPDRSTSYFPYGITLTITGFLLPFAAILACYC  
SMARILCQKDELIGLAVHKKKDKAVRMIIIVVIVFSISFFPFHLTKTIYLI  
RSSASLPCPTLQAFALAYKCTRPFASMNSVLDPIIFYFTQRFRESTRYLLD  
KMSSKWRQDHCISYGS

Fig. 4

ATGGAGAAGGTGGACATGAATACATCACAGGAACAAGGTCTCTGCCAGTTC  
TCAGAGAAGTACAAGCAAGTCTACCTCTCCCTGGCCTACAGTATCATCTTT  
ATCCTAGGGCTGCCACTAAATGGCACTGTCTTGTGGCACTCCTGGGGCCAA  
ACCAAGCGCTGGAGCTGTGCCACCACCTATCTGGTGAACCTGATGGTGGCC  
GACCTGCTTTATGTGCTATTGCCCTTCCTCATCATCACCTACTCACTAGAT  
GACAGGTGGCCCTTCGGGGAGCTGCTCTGCAAGCTGGTGCACCTTCCTGTTC  
TATATCAACCTTTACGGCAGCATCCTGCTGCTGACCTGCATCTCTGTGCAC  
CAGTTCCTAGGTGTGTGCCACCCACTGTGTTTCGCTGCCCTACCGGACCCGC  
AGGCATGCCTGGCTGGGCACCAGCACCACCTGGGCCCTGGTGGTCCCTCCAG  
CTGCTGCCCACACTGGCCTTCTCCACACGGACTACATCAATGGCCAGATG  
ATCTGGTATGACATGACCAGCCAAGAGAATTTTGATCGGCTTTTTGCCTAC  
GGCATAGTTCTGACATTGTCTGGCTTTCTTTCCCTCCTTGGTCATTTTGGT  
GTGCTATTCAGTATGGTCAGGAGCCTGATCAAGCCAGAGGAGAACCTCAT  
GAGGACAGGCAACACAGCCCGAGCCAGGTCCATCCGGACCATCCTACTGGT  
GTGTGGCCTCTTCACCCTCTGTTTTGTGCCCTTCCATATCACTCGCTCCTT  
CTACCTCACCATCTGCTTTCTGCTTTCTCAGGACTGCCAGCTCTTGATGGC  
AGCCAGTGTGGCCTACAAGATATGGAGGCCTCTG

Fig. 5

TAAAAGCTATGCAGGATAAAATGGGAGATACAGAGTAAA

- 4/7 -

FIG. 6

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : nrdb

Q: 15 CQFSEKYKQVYLSLAYSIIIFILGLPLNGTVLWHSWGQTKRWSCATTYLVNEMVADLLYVL

C.F.E::KQV.L.L.YS::F:LGLPLN..V: . W ..K. : .T.Y::NL.:ADLLYV.

H: 13 CTFHEEFKQVLLPLVYSVVPLLGLPLNAVVGQIWLARKALTRTTIYMLNLAMADLLYVC

-LPFLIITYSLDDRWPFGRLCLKLVHFLFYINLYGSILLLTCSVHQFLGVCHPLCSL-P

LP.LI..Y: .D WPGF:..CK.V.F FY.NL:GSIL.LTCISV...:G:CHPL.S .

SLPILLIYNYTQKDYWPGDFTCKFVRFOFYTNLHGSILFLTCISVQRYMGICHPLASWHK

YRTRRHAWLGTSTTWALVVLQLLPTLAFSHTDYINGQMIWYDMTSQENFDRLFAYGIVLT

.WL ....W :V:.Q.LPT..F:.T. .... YD:..... ..F.YGI.LT

KKGKKLTWLVCAAVWFIVIAQCLPTFVFASTGTQRNRTVCYDLSPDRSTSYFPYGITLT


LSGFL 197

::GFL

ITGFL 197

- 5/7 -

Fig. 7



- 6/7 -




Fig. 8

- 77 -




Fig. 9



## SEQUENCE LISTING

<110> Bayer AG

<120> REGULATION OF HUMAN P2Y-LIKE G PROTEIN-COUPLED RECEPTOR

<130> Lio059 Foreign Countries

<140>

<141>

<150> US 60/203,582

<151> 2000-05-11

<150> ATT. DOCKET 00299

<151> 2001-02-21

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 3143

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (520)..(1373)

<400> 1

aagggtcact tgctactcta ctatggccta tgtggtagg accaaattgt gggcagtttc 60  
ggccctctgg aatatacctg cttttctggc tagaatacct ccccttgagg attttctgac 120  
tctatgcaat ggattctagc aggaggagac acagagctgg aggttctgag taccctgttt 180  
aaatgacagt gtcacccac caccatttct atcacaaccc agcctagagt agacagcata 240  
caagtccatg taaggccaac cctttggacc tggttaagtct agacgccag ctttggaga 300  
ttatttggcc ctgttggaat actctatttt cctggggttg gtctctttta aacaaggcct 360  
ctgactagac ttggggggac aaagtgaat gccgggttg ggcagaggct gatgccatgc 420  
tgaggtcatg atgttatgct gtccattttg ctcccttcca ggggaagcag aagcgggagc 480  
cgctgtggag ctctgctcct ggaggggagcc tccggggaca tggagaaggt ggacatgaat 540  
acatcacagg aacaaggctc ctgccagttc tcagagaagt acaagcaagt ctacctctcc 600  
ctggcctaca gtatcatctt taccctaggg ctgccactaa atggcactgt ctgtggcac 660  
tctctggggc aaaccaagcg ctggagctgt gccaccacct atctggtgaa cctgatggtg 720  
gccgacctgc tttatgtgct attgcccttc ctcatcatca cctactcact agatgacagg 780  
tggcccttcg gggagctgct ctgcaagctg gtgcaactcc tgttctatat caacctttac 840  
ggcagcatcc tgctgctgac ctgcatctct gtgcaccagt tctaggtgt gtgccacca 900  
ctgtgttcgc tgccctaccg gaccgcagg catgcctggc tgggcaccag caccacctgg 960  
gccctggtgg tctccagct gctgccaca ctggccttct cccacacgga ctacatcaat 1020

```

ggccagatga tctggtatga catgaccagc caagagaatt ttgatcggt tttgcctac 1080
ggcatagttc tgacattgtc tggctttctt tccctccttg gtcatttttg tgtgctattc 1140
actgatggtc aggagcctga tcaagccaga ggagaacctc atgaggacag gcaacacagc 1200
ccgagccagg tccatccgga ccatcctact ggtgtgtggc ctcttcaccc tctgttttgt 1260
gcccttccat atcactcgct ccttctacct caccatctgc tttctgcttt ctcaggactg 1320
ccagctcttg atggcagcca gtgtggccta caagatatgg aggcctctgg tgagtgtgag 1380
cagctgcctc aaccagtc tgtactttct tcaaggggg gcaaaaatag agtcaggctc 1440
ctccagaaac tgaggcagaa caagttgggt gagcatccag ctgggaggaa gagatgcca 1500
gggttgaaca gatctgggt atgccaagg gaagcttggg aaaaacgagc tccaacacca 1560
ctagcaacaa cttgtttgta cacagatgag tgctggtggg agaggggctc aagacctcct 1620
aaaagtgtcc tgctgcaaag gacactttta tattgatgtt aagtgagttt aaaataagag 1680
tatggagaga gccactaaaa caaaggaaaa ctttcttaaa gagagctgac attggtctct 1740
tgtcattcag gtctcagctc aaatgtcacc ttctcagaga ccactcctgc ccacctagc 1800
taatgttgac ctctctcctc ataaccaat cactgtattc ccttatatat tgtctttgca 1860
acatttatta ctatctggac ttggtgattc atttacttat ttatgatctc tttccactga 1920
attatatgct ccaataggac agagatctcc tctgatggct gaccctcaa taccagctc 1980
catagcaggg cctggcacat agtaaggga caacagatag gggctgaatg aatgagttag 2040
caaatggacc tgtaaatgaa acccttacta tgaaagagca ctttgcattg gaggaactca 2100
tttaacctc acaataatcc cttgtgtgg aggccattgt ttctccatt tacagagaag 2160
gaaactgaca cgcacagctc aaagtaactt gttcaggctt acccagtggg agaatgcca 2220
gatcataggg ttgaatggag ctttcaaagc caggcagtgg cctctgaagc acatgctcct 2280
aagcgtgaaa gctatgcccc catccaaaca ccagcctaga gctggcccaa gttctccttg 2340
acaatatcgg cttgtcattt taggccggct cgcttgttga cacagtgtgt gttatctgca 2400
gaacactgag gagacctgt gtggtctttt actacatttc ttaaccagtg tttttgttag 2460
taaaagctat gcaggataaa atgggagata cagagtaaag tggcttcaag aaaactgatt 2520
cgcttcattt ttatttaaat ttaaacatga tggtggagat tatgaaaaaa aacttcatca 2580
atgtcttaag tcataatgat gtttattccc taaaaagact ttttttagtt aagatgcaag 2640
gtaatccaaa aagataacct taaaaaaac ctctcattta taacaataat gatttccaag 2700
gatttctcag gtctatacat aacattatct aggetgggca cagtggctca tgctgtaat 2760
cccagcactt tgggaggcca aggcgggagg atcacctgag gtcaggagtt cgagaccaat 2820
ctggccaaca tgggtgaacc ccatctctac taaaaatata aaaattagct gggcgtgggtg 2880
gcgggtgcct ataatcccag ctactcggga ggctgagaaa ggagaatcgc ttgaacctcg 2940
gaggcggagg ttgcagttag ctgaaactac gccactgcac tccagcctgg gcaacaagag 3000
cgaaactctt aaaaaaaaaa ttatctaata attcactaat ctccctatga agagaagggtg 3060
gttaaatctt ttttataaga aacaagcata acccctcatt actatctcac tccaattatg 3120
ggaaatgtct gagtaaacca tgt 3143

```

&lt;210&gt; 2

&lt;211&gt; 295

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Glu Lys Val Asp Met Asn Thr Ser Gln Glu Gln Gly Leu Cys Gln
  1                      5                      10                      15

```

```

Phe Ser Glu Lys Tyr Lys Gln Val Tyr Leu Ser Leu Ala Tyr Ser Ile

```

20 25 30  
 Ile Phe Ile Leu Gly Leu Pro Leu Asn Gly Thr Val Leu Trp His Ser  
 35 40 45  
 Trp Gly Gln Thr Lys Arg Trp Ser Cys Ala Thr Thr Tyr Leu Val Asn  
 50 55 60  
 Leu Met Val Ala Asp Leu Leu Tyr Val Leu Leu Pro Phe Leu Ile Ile  
 65 70 75 80  
 Thr Tyr Ser Leu Asp Asp Arg Trp Pro Phe Gly Glu Leu Leu Cys Lys  
 85 90 95  
 Leu Val His Phe Leu Phe Tyr Ile Asn Leu Tyr Gly Ser Ile Leu Leu  
 100 105 110  
 Leu Thr Cys Ile Ser Val His Gln Phe Leu Gly Val Cys His Pro Leu  
 115 120 125  
 Cys Ser Leu Pro Tyr Arg Thr Arg Arg His Ala Trp Leu Gly Thr Ser  
 130 135 140  
 Thr Thr Trp Ala Leu Val Val Leu Gln Leu Leu Pro Thr Leu Ala Phe  
 145 150 155 160  
 Ser His Thr Asp Tyr Ile Asn Gly Gln Met Ile Trp Tyr Asp Met Thr  
 165 170 175  
 Ser Gln Glu Asn Phe Asp Arg Leu Phe Ala Tyr Gly Ile Val Leu Thr  
 180 185 190  
 Leu Ser Gly Phe Leu Ser Leu Leu Gly His Phe Gly Val Leu Phe Thr  
 195 200 205  
 Asp Gly Gln Glu Pro Asp Gln Ala Arg Gly Glu Pro His Glu Asp Arg  
 210 215 220  
 Gln His Ser Pro Ser Gln Val His Pro Asp His Pro Thr Gly Val Trp  
 225 230 235 240  
 Pro Leu His Pro Leu Phe Cys Ala Leu Pro Tyr His Ser Leu Leu Leu  
 245 250 255  
 Pro His His Leu Leu Ser Ala Phe Ser Gly Leu Pro Ala Leu Asp Gly  
 260 265 270  
 Ser Gln Cys Gly Leu Gln Asp Met Glu Ala Ser Val Lys Ala Met Gln

275                      280                      285  
 Asp Lys Met Gly Asp Thr Glu  
 290                      295  
  
 <210> 3  
 <211> 328  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 3  
 Met Ser Met Ala Asn Phe Thr Gly Gly Arg Asn Ser Cys Thr Phe His  
 1                      5                      10                      15  
  
 Glu Glu Phe Lys Gln Val Leu Leu Pro Leu Val Tyr Ser Val Val Phe  
 20                      25                      30  
  
 Leu Leu Gly Leu Pro Leu Asn Ala Val Val Ile Gly Gln Ile Trp Leu  
 35                      40                      45  
  
 Ala Arg Lys Ala Leu Thr Arg Thr Thr Ile Tyr Met Leu Asn Leu Ala  
 50                      55                      60  
  
 Met Ala Asp Leu Leu Tyr Val Cys Ser Leu Pro Leu Leu Ile Tyr Asn  
 65                      70                      75                      80  
  
 Tyr Thr Gln Lys Asp Tyr Trp Pro Phe Gly Asp Phe Thr Cys Lys Phe  
 85                      90                      95  
  
 Val Arg Phe Gln Phe Tyr Thr Asn Leu His Gly Ser Ile Leu Phe Leu  
 100                      105                      110  
  
 Thr Cys Ile Ser Val Gln Arg Tyr Met Gly Ile Cys His Pro Leu Ala  
 115                      120                      125  
  
 Ser Trp His Lys Lys Lys Gly Lys Lys Leu Thr Trp Leu Val Cys Ala  
 130                      135                      140  
  
 Ala Val Trp Phe Ile Val Ile Ala Gln Cys Leu Pro Thr Phe Val Phe  
 145                      150                      155                      160  
  
 Ala Ser Thr Gly Thr Gln Arg Asn Arg Thr Val Cys Tyr Asp Leu Ser  
 165                      170                      175  
  
 Pro Pro Asp Arg Ser Thr Ser Tyr Phe Pro Tyr Gly Ile Thr Leu Thr  
 180                      185                      190

Ile Thr Gly Phe Leu Leu Pro Phe Ala Ala Ile Leu Ala Cys Tyr Cys  
 195 200 205

Ser Met Ala Arg Ile Leu Cys Gln Lys Asp Glu Leu Ile Gly Leu Ala  
 210 215 220

Val His Lys Lys Lys Asp Lys Ala Val Arg Met Ile Ile Ile Val Val  
 225 230 235 240

Ile Val Phe Ser Ile Ser Phe Phe Pro Phe His Leu Thr Lys Thr Ile  
 245 250 255

Tyr Leu Ile Val Arg Ser Ser Ala Ser Leu Pro Cys Pro Thr Leu Gln  
 260 265 270

Ala Phe Ala Ile Ala Tyr Lys Cys Thr Arg Pro Phe Ala Ser Met Asn  
 275 280 285

Ser Val Leu Asp Pro Ile Leu Phe Tyr Phe Thr Gln Arg Lys Phe Arg  
 290 295 300

Glu Ser Thr Arg Tyr Leu Leu Asp Lys Met Ser Ser Lys Trp Arg Gln  
 305 310 315 320

Asp His Cys Ile Ser Tyr Gly Ser  
 325

<210> 4

<211> 850

<212> DNA

<213> Homo sapiens

<400> 4

atggagaagg tggacatgaa tacatcacag gaacaaggtc tctgccagtt ctgagagaag 60  
 tacaagcaag tctacctctc cctggcctac agtatcatct ttatcctagg gctgccacta 120  
 aatggcactg tcttgtggca ctccctggggc caaaccaagc gctggagctg tgccaccacc 180  
 tatctggtga acctgatggt ggccgacctg ctttatgtgc tattgccctt cctcatcacc 240  
 acctactcac tagatgacag gtggcccttc ggggagctgc tctgcaagct ggtgcacttc 300  
 ctgtttctata tcaaccttta cggcagcatc ctgctgctga cctgcatctc tgtgcaccag 360  
 ttccctagggtg tgtgccaccc actgtgttcg ctgccctacc ggacccgcag gcatgcctgg 420  
 ctgggaccca gcaccacctg ggccctgggtg gtccctccagc tgctgcccac actggccttc 480  
 tcccacacgg actacatcaa tggccagatg atctggtatg acatgaccag ccaagagaat 540  
 tttgatcggc tttttgccta cggcatagtt ctgacattgt ctggctttct ttccctcctt 600  
 ggtcattttg gtgtgctatt cactgatggt caggagcctg atcaagccag aggagaacct 660  
 catgaggaca ggcaacacag cccgagccag gtccatccgg accatcctac tgggtgtgtg 720  
 cctcttcacc ctctgttttg tgcccttcca tatcactcgc tccttctacc tcaccatctg 780  
 ctttctgctt tctcaggact gccagctctt gatggcagcc agtgtggcct acaagatatg 840

gaggcctctg

850

<210> 5

<211> 39

<212> DNA

<213> Homo sapiens

<400> 5

taaaagctat gcaggataaa atgggagata cagagtaaa

39